预约演示
更新于：2025-12-05
Elinzanetant
依林扎奈坦
更新于：2025-12-05
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 加拿大 (2025-07-01), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C33H35F7N4O3 |
InChIKeyDWRIJNIPBUFCQS-DQEYMECFSA-N |
CAS号929046-33-3 |
关联
27
项与 依林扎奈坦 相关的临床试验NCT06219902
A Randomized, Double-blind, Placebo- and Active-controlled, 4-period, Crossover Study to Investigate Effects of Elinzanetant on Simulated Driving Performance and Cognitive Function in Healthy Women
Researchers are looking for a better way to treat vasomotor symptoms (VMS), also known as hot flashes.
Hot flashes are intense and sudden feelings of heat along with sweating and reddening of the skin. These are common for women going through the menopause but can also occur in men. Such symptoms are called VMS and are caused by changes in sex hormone levels.
The study treatment, elinzanetant, is being tested for the treatment of VMS in both men and women. It works by blocking the activity of a substance called neurokinin, which is thought to play a role in starting hot flashes.
Elinzanetant may cause lasting effects like sleepiness and tiredness. Such effects may make driving unsafe.
The main purpose of this study is to learn how elinzanetant affects the ability to drive the next day in healthy women.
For this, researchers will study participants' ability to keep a stable position within their lane while driving on a straight road on a computer-based driving test (also known as a driving simulator).
In this study, participants will take 2 different doses of elinzanetant, another drug called zopiclone, and matching placebos to these drugs.
Zopiclone helps treat sleeping problems. A placebo looks like a study drug but does not have any medicine in it.
Participants will take elinzanetant, zopiclone, and their matching placebos by mouth.
This study will have 4 treatment periods with each period lasting 6 days. In each period, participants will receive one of the following treatments in an order assigned to them randomly (by chance):
* dose A of elinzanetant and a zopiclone placebo
* dose B of elinzanetant and a zopiclone placebo
* zopiclone 7.5 milligrams (mg) and elinzanetant placebo
* elinzanetant placebo and zopiclone placebo
Each participant will be in the study for around 15 weeks with up to 6 visits to the study site.
Participants will visit the study site:
* once before the treatment starts, so the study doctors and their team can check on their health and confirm if the participant can join the study
* once in each of the 4 treatment periods for a 6-day stay at the study site with a gap of 14 days between each period. During each stay, they will take the assigned treatment from Days 1 to 5 and the driving test on Days 2 and 6
* once, 2 to 3 days after their last treatment so the study doctors and their team can check on their health
During the study, the doctors and their study team will:
* check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG)
* check the participants' ability to drive and their brain function and level of sleepiness using different tests including a driving simulator test
* check the level of the study drugs in participants' blood
* ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think they are related to the study treatment or not.
Hot flashes are intense and sudden feelings of heat along with sweating and reddening of the skin. These are common for women going through the menopause but can also occur in men. Such symptoms are called VMS and are caused by changes in sex hormone levels.
The study treatment, elinzanetant, is being tested for the treatment of VMS in both men and women. It works by blocking the activity of a substance called neurokinin, which is thought to play a role in starting hot flashes.
Elinzanetant may cause lasting effects like sleepiness and tiredness. Such effects may make driving unsafe.
The main purpose of this study is to learn how elinzanetant affects the ability to drive the next day in healthy women.
For this, researchers will study participants' ability to keep a stable position within their lane while driving on a straight road on a computer-based driving test (also known as a driving simulator).
In this study, participants will take 2 different doses of elinzanetant, another drug called zopiclone, and matching placebos to these drugs.
Zopiclone helps treat sleeping problems. A placebo looks like a study drug but does not have any medicine in it.
Participants will take elinzanetant, zopiclone, and their matching placebos by mouth.
This study will have 4 treatment periods with each period lasting 6 days. In each period, participants will receive one of the following treatments in an order assigned to them randomly (by chance):
* dose A of elinzanetant and a zopiclone placebo
* dose B of elinzanetant and a zopiclone placebo
* zopiclone 7.5 milligrams (mg) and elinzanetant placebo
* elinzanetant placebo and zopiclone placebo
Each participant will be in the study for around 15 weeks with up to 6 visits to the study site.
Participants will visit the study site:
* once before the treatment starts, so the study doctors and their team can check on their health and confirm if the participant can join the study
* once in each of the 4 treatment periods for a 6-day stay at the study site with a gap of 14 days between each period. During each stay, they will take the assigned treatment from Days 1 to 5 and the driving test on Days 2 and 6
* once, 2 to 3 days after their last treatment so the study doctors and their team can check on their health
During the study, the doctors and their study team will:
* check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG)
* check the participants' ability to drive and their brain function and level of sleepiness using different tests including a driving simulator test
* check the level of the study drugs in participants' blood
* ask the participants questions about how they are feeling and what adverse events they are having.
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think they are related to the study treatment or not.
开始日期2024-01-08 |
申办/合作机构 |
NCT06112756
A Randomized, Parallel-group Treatment, Phase 2, Double-blind Pilot Study to Investigate the Efficacy and Safety of Elinzanetant Compared With Placebo for Treatment of Sleep Disturbances Associated With Menopause.
Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause.
Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop. Sleep disturbances, for example, frequent waking up at night, are a common and bothersome symptom associated with menopause that affects women's quality of life.
The study treatment Elinzanetant (also called BAY 3427080) is under development to treat symptoms like hot flashes which are caused by hormonal changes associated with menopause. It may block the activity of a protein that has been found to contribute to sleep disturbances.
The main purpose of this study is to learn how does elinzanetant affect sleep disturbances associated with menopause as measured on a sleep test called polysomnography (PSG) as compared with placebo.
For this, the researchers will analyze
* change in the total number of minutes a participant wakes up at night after going to sleep after 4 weeks of treatment compared to before treatment
* change in the total number of minutes a participant wakes up at night after going to sleep after 12 weeks of treatment compared to before treatment
* change in the participant's total time asleep while in bed after 4 and 12 weeks of treatment compared to before treatment.
The study participants will be randomly (by chance) assigned to one of two treatment groups. Dependent on the group, they will take elinzanetant or placebo for 12 weeks.
Each participant will be in the study for approximately 22 weeks (plus potential washout period), including a screening phase of up to 6 weeks, 12 weeks of treatment, and a follow up phase of 4 weeks after the end of treatment. 5 visits to the study site are planned.
During the study, the doctors and their study team will:
* take blood and urine samples
* do physical examinations
* check vital signs
* do sleep tests
* use an electronic hand-held device to record sleep quality and hot flashes at home
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop. Sleep disturbances, for example, frequent waking up at night, are a common and bothersome symptom associated with menopause that affects women's quality of life.
The study treatment Elinzanetant (also called BAY 3427080) is under development to treat symptoms like hot flashes which are caused by hormonal changes associated with menopause. It may block the activity of a protein that has been found to contribute to sleep disturbances.
The main purpose of this study is to learn how does elinzanetant affect sleep disturbances associated with menopause as measured on a sleep test called polysomnography (PSG) as compared with placebo.
For this, the researchers will analyze
* change in the total number of minutes a participant wakes up at night after going to sleep after 4 weeks of treatment compared to before treatment
* change in the total number of minutes a participant wakes up at night after going to sleep after 12 weeks of treatment compared to before treatment
* change in the participant's total time asleep while in bed after 4 and 12 weeks of treatment compared to before treatment.
The study participants will be randomly (by chance) assigned to one of two treatment groups. Dependent on the group, they will take elinzanetant or placebo for 12 weeks.
Each participant will be in the study for approximately 22 weeks (plus potential washout period), including a screening phase of up to 6 weeks, 12 weeks of treatment, and a follow up phase of 4 weeks after the end of treatment. 5 visits to the study site are planned.
During the study, the doctors and their study team will:
* take blood and urine samples
* do physical examinations
* check vital signs
* do sleep tests
* use an electronic hand-held device to record sleep quality and hot flashes at home
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
开始日期2023-11-08 |
申办/合作机构 |
CTIS2023-503968-16-00
A study to learn about how much elinzanetant gets absorbed in the blood and how safe it is in healthy participants when taken as different types of formulations
开始日期2023-09-25 |
申办/合作机构  Bayer AG [+1] |
100 项与 依林扎奈坦 相关的临床结果
登录后查看更多信息
100 项与 依林扎奈坦 相关的转化医学
登录后查看更多信息
100 项与 依林扎奈坦 相关的专利（医药）
登录后查看更多信息
35
项与 依林扎奈坦 相关的文献（医药）2025-12-01·Drug and therapeutics bulletin
▼Elinzanetant for menopause
Review
2025-11-01·DRUGS
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms
Review
作者: Young Moss, Stephanie ; Simon, James A ; Lee, Angie
Vasomotor symptoms (VMS) are considered the cardinal symptoms of menopause, affecting up to 80% of American women at some point during the menopausal transition. VMS, particularly if they are moderate to severe, frequent, or cause sleep disturbances, can have a negative impact on a woman's quality of life, physical and mental health, and professional life. Furthermore, VMS have been associated with negative health outcomes, including an increased risk of coronary heart disease and cognitive impairment. Menopausal hormonal therapy (MHT) is supported by level 1 evidence and can address many of the negative impacts associated with menopause, including VMS. However, not all women can take MHT (owing to having contraindications to their use) or choose not to take MHT. In addition to MHT, non-hormonal therapy options, which include neurokinin (NK)-targeted therapies, are also available. Fezolinetant (NK3 receptor antagonist) and the newly approved elinzanetant (NK1 and NK3 receptor antagonist) are non-hormonal treatment options approved for the treatment of VMS associated with menopause. These approvals expand the treatment options for women. A number of investigational agents are currently in phase 2 trials for potential future use for VMS; these include Q-122, PhytoSERM, NOE-115, GS1-144, and HS-10384. In this review, we highlight the recent advancements in our understanding of the pathophysiology of VMS and consider the current, new, and investigational treatment options for the treatment of VMS.
2025-11-01·JAMA Internal Medicine
The Growing Promise of Elinzanetant for Treatment of Menopausal Symptoms—Sustained Relief Without Hormones
Article
作者: Manson, JoAnn E. ; Mehta, Jaya M. ; Millstine, Denise M.
224
项与 依林扎奈坦 相关的新闻（医药）2025-12-04
N Engl J Med[Jour] AND 393[volume] AND 1[issue]
新英格兰医学杂志 393卷1期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: Defining Health Care “Corporatization”
美国医疗保健的企业化：界定医疗保健“企业化”
E.C. Fuse Brown
N Engl J Med; July 3, 2025; 393(1)：1-3
2
Self-Neglect in Older People — A Clinical, Social, and Ethical Dilemma
老年人自我忽视——临床、社会和伦理困境
K. Lees Haggerty and D.B. Reuben
N Engl J Med; July 3, 2025; 393(1)：4-6
3
Biologic Drugs and Medicare Price Negotiation
生物制剂与医保价格谈判
T.J. Hwang , N.L. Keating , and S.B. Dusetzina
N Engl J Med; July 3, 2025; 393(1)：6-9
4
The Autopsy Report
尸检报告
K. Klara
N Engl J Med; July 3, 2025; 393(1)：9-11
ORIGINAL ARTICLES（论著）
5
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
结肠癌辅助化疗后的结构化运动
K.S. Courneya and Others
N Engl J Med; July 3, 2025; 393(1)：13-25
6
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
与司美格鲁肽相比，替西帕肽治疗肥胖症的效果
L.J. Aronne and Others
N Engl J Med; July 3, 2025; 393(1)：26-36
7
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
局部晚期头颈癌的新型辅助和辅助帕博利珠单抗治疗
R. Uppaluri and Others
N Engl J Med; July 3, 2025; 393(1)：37-50
8
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
奥贝胆酸在心血管高危患者中的安全性和有效性
S.J. Nicholls and Others
N Engl J Med; July 3, 2025; 393(1)：51-61
REVIEW ARTICLE（综述）
9
Forensic Pathology
法医病理学
R.D. Folkerth , B.A. Sampson , and J.K. Graham
N Engl J Med; July 3, 2025; 393(1)：62-71
IMAGES IN CLINICAL MEDICINE（临床医学影像）
10
Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis
抗中性粒细胞胞浆抗体相关性血管炎导致的弥漫性肺泡出血
I.S. Lee
N Engl J Med; July 3, 2025; 393(1)：72
11
Frostbite Injury from Inhaled Nitrous Oxide Use
吸入一氧化二氮导致的冻伤损伤
M. Patrizio and M. Hayden
N Engl J Med; July 3, 2025; 393(1)：e1
CLINICAL PROBLEM-SOLVING（临床问题解决）
12
Caving In to Pressure
屈服于压力
S.I. Gomez-Villegas and Others
N Engl J Med; July 3, 2025; 393(1)：73-79
EDITORIALS（社论）
13
The Corporatization of U.S. Health Care — A New Perspective Series
美国医疗保健的企业化——一个新的观点与视角系列
D. Malina and Others
N Engl J Med; July 3, 2025; 393(1)：81-82
14
Extending Cancer Survival with Exercise — Time for Oncology to Act
通过运动延长癌症患者生存期——肿瘤学该行动了
M.L. Irwin
N Engl J Med; July 3, 2025; 393(1)：82-84
15
Semaglutide and Tirzepatide to Treat Obesity
司美格鲁肽和替西帕肽治疗肥胖症
F.L. Greenway
N Engl J Med; July 3, 2025; 393(1)：84-85
16
Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer
在头颈癌根治性治疗中运用免疫疗法
A.J. Rosenberg and E.E. Vokes
N Engl J Med; July 3, 2025; 393(1)：85-87
SOUNDING BOARD（议事堂）
17
From the National Academy of Medicine: Climate Change and Human Health — A Research Agenda for Action
来自美国国家医学院的观点：气候变化与人类健康——行动研究议程
V.J. Dzau and Others
N Engl J Med; July 3, 2025; 393(1)：88-92
CORRESPONDENCE（读者来信）
18
Lifesaving Diagnosis through Prenatal Genomic Sequencing
通过产前基因组测序作出挽救生命的诊断
N Engl J Med; July 3, 2025; 393(1)：93-95
19
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
2型糖尿病患者强化血压控制
N Engl J Med; July 3, 2025; 393(1)：95-98
20
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections
血流感染患者抗生素治疗7天与14天的对比
N Engl J Med; July 3, 2025; 393(1)：98-101
21
Dapagliflozin in Patients Undergoing TAVI
接受经导管主动脉瓣植入术患者使用达格列净的情况
N Engl J Med; July 3, 2025; 393(1)：101-103
22
Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy
关于利司扑兰用于脊髓性肌萎缩症产前治疗的进一步评论
N Engl J Med; July 3, 2025; 393(1)：103-104
N Engl J Med[Jour] AND 393[volume] AND 2[issue]
新英格兰医学杂志 393卷2期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Who Will Care for America? Immigration Policy and the Coming Health Workforce Crisis
谁来关照美国？移民政策与即将到来的医疗劳动力危机
P.M.G. Santos , R. Jagsi , and C.I.A. Oronce
N Engl J Med; July 10, 2025; 393(2)：105-107
2
Exclusion of Elective Care from Hospital Financial Assistance Policies — Arresting a Troubling Development
医院财务援助政策中排除择期护理——遏制令人不安的发展态势
M.A. Hall and J. Garber
N Engl J Med; July 10, 2025; 393(2)：107-110
3
Libraries Burned, a Life Lived
图书馆被焚，人生如旅
T. Vijayan
N Engl J Med; July 10, 2025; 393(2)：110-111
ORIGINAL ARTICLES（论著）
4
As-Needed Albuterol–Budesonide in Mild Asthma
按需使用沙丁胺醇-布地奈德治疗轻度哮喘
C. LaForce and Others
N Engl J Med; July 10, 2025; 393(2)：113-124
5
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates
心血管危险因素对终生风险的全球影响
The Global Cardiovascular Risk Consortium
N Engl J Med; July 10, 2025; 393(2)：125-138
6
Intravenous Tenecteplase before Thrombectomy in Stroke
卒中血栓切除术前静脉注射替奈普酶
Z. Qiu and Others
N Engl J Med; July 10, 2025; 393(2)：139-150
7
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer
Inavolisib治疗PIK3CA突变型晚期乳腺癌的总生存期
K.L. Jhaveri and Others
N Engl J Med; July 10, 2025; 393(2)：151-161
REVIEW ARTICLE（综述）
8
Juvenile Idiopathic Arthritis
幼年特发性关节炎
C.I. Sandborg , G.S. Schulert , and Y. Kimura
N Engl J Med; July 10, 2025; 393(2)：162-174
IMAGES IN CLINICAL MEDICINE（临床医学影像）
9
Whipple’s Disease with Endocarditis
伴有心内膜炎的惠普尔病
P. Ackermann and M.A. Borger
N Engl J Med; July 10, 2025; 393(2)：175
10
Incarcerated Femoral Hernia
嵌顿性股疝
P. Rana and H. Jivani
N Engl J Med; July 10, 2025; 393(2)：e2
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
11
Case 19-2025: A 69-Year-Old Man with Headache and Ataxia
病例19-2025：一名69岁男性，头痛且共济失调
A. Venkatesan and Others
N Engl J Med; July 10, 2025; 393(2)：176-184
EDITORIALS（社论）
12
Your Combination Asthma Inhaler — Don’t Leave Home without It!
你的联合哮喘吸入器——出门别忘了带！
J.M. Drazen
N Engl J Med; July 10, 2025; 393(2)：186-187
13
Estimates of Cardiovascular Risks and Benefits — When Knowing Is Not Enough
心血管风险和获益的评估——光知晓并不够
G.A. Mensah
N Engl J Med; July 10, 2025; 393(2)：187-189
14
Thrombolysis before Thrombectomy in Stroke — A Bridge Not Fallen
卒中血栓切除术前溶栓治疗——一座未坍塌的桥梁
T.W. Leung
N Engl J Med; July 10, 2025; 393(2)：189-191
SOUNDING BOARD（议事堂）
15
From the National Academy of Medicine: Transforming Health Care — Shared Commitments for a Learning Health System
来自美国国家医学院的观点：转变医疗保健模式——构建学习型医疗系统的共同承诺
J.L. Madara and Others
N Engl J Med; July 10, 2025; 393(2)：192-197
CORRESPONDENCE（通信）
16
Expansion of tetM-Carrying Neisseria gonorrhoeae in the United States, 2018–2024
2018-2024年美国携带tetM的淋病奈瑟菌的扩散情况
N Engl J Med; July 10, 2025; 393(2)：198-200
17
Atrial Appendage Closure after Ablation for Atrial Fibrillation
心房颤动消融术后左心耳封堵
N Engl J Med; July 10, 2025; 393(2)：200-203
18
Tumor-Infiltrating Clonal Hematopoiesis
肿瘤浸润性克隆性造血
N Engl J Med; July 10, 2025; 393(2)：203-205
19
Wealth and Mortality in the United States and Europe
美国和欧洲的财富与死亡率
N Engl J Med; July 10, 2025; 393(2)：205-207
20
Addressing Alcohol Use
应对酒精使用问题
N Engl J Med; July 10, 2025; 393(2)：207-208
N Engl J Med[Jour] AND 393[volume] AND 3[issue]
新英格兰医学杂志 393卷3期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Role of Public Health Agencies in Creating Vaccine Policy
公共卫生机构在制定疫苗政策中的作用
P. Marks
N Engl J Med; July 17, 2025; 393(3):209-211
2
New Mammography Tools — The Need for Clinically Meaningful Assessment Standards
新的乳腺钼靶工具——需要有临床意义的评估标准
B. Hyams , K. Kerlikowske , and R.F. Redberg
N Engl J Med; July 17, 2025; 393(3):211-213
3
The Second Life of Jacqui B.
Jacqui B.的第二人生。
M. Earnest and P. Khazanie
N Engl J Med; July 17, 2025; 393(3):214-215
ORIGINAL ARTICLES（论著）
4
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
杜伐鲁单抗在胃和胃食管结癌围手术期的应用
Y.Y. Janjigian and Others
N Engl J Med; July 17, 2025; 393(3):217-230
5
First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate
强的松或甲氨蝶呤治疗肺结节病的一线治疗
V. Kahlmann and Others
N Engl J Med; July 17, 2025; 393(3):231-242
6
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
环磷酰胺和环孢素预防移植物抗宿主病
D.J. Curtis and Others
N Engl J Med; July 17, 2025; 393(3):243-254
7
Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis
小儿肠胃炎急诊后多剂量昂丹司琼的疗效
S.B. Freedman and Others
N Engl J Med; July 17, 2025; 393(3):255-266
8
Brief Report: Rapid Recovery of Donor Hearts for Transplantation after Circulatory Death
简要报告：供体心脏在循环性死亡后快速恢复
A.M. Williams and Others
N Engl J Med; July 17, 2025; 393(3):267-274
9
Brief Report: On-Table Reanimation of a Pediatric Heart from Donation after Circulatory Death
简要报告：一名循环死亡后捐赠的儿童心脏在手术台上复活
J.A. Kucera , D.M. Overbey , and J.W. Turek
N Engl J Med; July 17, 2025; 393(3):275-280
REVIEW ARTICLE(综述)
10
The Spectrum of Fragile X Disorders
脆性X染色体紊乱谱系
R.J. Hagerman and P.J. Hagerman
N Engl J Med; July 17, 2025; 393(3):281-288
IMAGES IN CLINICAL MEDICINE（临床医学影像学）
11
Acrometastases
Acrometastases
H. O’Rourke and M. Iddawela
N Engl J Med; July 17, 2025; 393(3):289
12
Microcysts in Lithium-Induced Nephropathy
锂诱发肾病中的微囊
C.-H. Liao and K.-L. Liu
N Engl J Med; July 17, 2025; 393(3):e3
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马赛诸塞州总医院病例记录）
13
Case 20-2025: An 86-Year-Old Woman with Neck Swelling and Dysphagia
病例20-2025:86岁女性，颈部肿胀和吞咽困难
M.L. Russell and Others
N Engl J Med; July 17, 2025; 393(3):290-300
EDITORIALS（社论）
14
New Perioperative Strategy in Gastric Cancer
胃癌围手术期新策略
K. Shitara
N Engl J Med; July 17, 2025; 393(3):302-303
15
Methotrexate as Initial Therapy for Symptomatic Pulmonary Sarcoidosis?
甲氨蝶呤作为症状性肺结节病的初始治疗？
R.P. Baughman and E.E. Lower
N Engl J Med; July 17, 2025; 393(3):303-305
CORRESPONDENCE（通信）
16
Monoclonal Anti–Platelet Factor 4 Antibodies in Recurrent Pregnancy Loss
单克隆抗血小板因子4抗体在复发性妊娠丢失中的作用
N Engl J Med; July 17, 2025; 393(3):306-309
17
Apixaban for Cancer-Associated Venous Thromboembolism
阿哌沙班治疗癌症相关静脉血栓栓塞
N Engl J Med; July 17, 2025; 393(3):309-312
N Engl J Med[Jour] AND 393[volume] AND 4[issue]
新英格兰医学杂志 393卷4期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Brain Death in Pregnancy — Abortion, Advance-Directive, or End-of-Life Law?
妊娠期脑死亡——人工流产、预先指示还是临终法律问题？
K. Watson
N Engl J Med; July 24, 2025; 393(4):313-315
2
The Faulty Logic behind the Supreme Court’s Failure to Protect Trans Minors
最高法院未能保护跨性别未成年人的逻辑谬误
S. Skinner-Thompson
N Engl J Med; July 24, 2025; 393(4):316-318
3
The Promise of Real-World Data for Research — What Are We Missing?
现实世界数据研究的前景——我们错过了什么？
A.B. Abbasi , L.H. Curtis , and R.M. Califf
N Engl J Med; July 24, 2025; 393(4):318-321
4
Avocado and Salt
鳄梨和盐
G. Yi
N Engl J Med; July 24, 2025; 393(4):321-323
ORIGINAL ARTICLES(论著)
5
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy
未接受胰岛素治疗的2型糖尿病患者的每周固定剂量艾塞那肽胰岛素
J. Rosenstock and Others
N Engl J Med; July 24, 2025; 393(4):325-335
6
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
德曲妥珠单抗或雷莫芦单抗联合紫杉醇治疗胃癌
K. Shitara and Others
N Engl J Med; July 24, 2025; 393(4):336-348
7
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
塔拉他单抗在小细胞肺癌铂基化疗后的疗效
G. Mountzios and Others
N Engl J Med; July 24, 2025; 393(4):349-361
8
Ivermectin to Control Malaria — A Cluster-Randomized Trial
伊维菌素控制疟疾-一项集群随机试验
C. Chaccour and Others
N Engl J Med; July 24, 2025; 393(4):362-375
REVIEW ARTICLE(综述)
9
Medical Education: Competency-Based Medical Education at the Front Lines of Patient Care
医学教育：位于患者护理第一线的基于能力的医学教育
D. Cooper and E.S. Holmboe
N Engl J Med; July 24, 2025; 393(4):376-388
IMAGES IN CLINICAL MEDICINE(临床医学影像)
10
Löfgren’s Syndrome
洛夫格伦综合征
M. Hassan
N Engl J Med; July 24, 2025; 393(4):389
11
Hydroxychloroquine Retinal Toxicity
羟氯喹视网膜毒性
A. Donnelly and N. Horgan
N Engl J Med; July 24, 2025; 393(4):e4
INTERACTIVE MEDICAL CASE(互动式医疗案例)
12
A Case of Crackles
一例啰音病例
J.I. Hsu and Others
N Engl J Med; July 24, 2025; 393(4):e5
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马赛诸塞州总医院病例记录）
13
Case 21-2025: A 75-Year-Old Man with Cough, Dyspnea, and Hypoxemia
病例21-2025:75岁男性，咳嗽、呼吸困难伴低氧血症
A.M. Anandaiah and Others
N Engl J Med; July 24, 2025; 393(4):390-399
EDITORIALS(社论)
14
Weekly Insulins and Therapeutic Burden in Type 2 Diabetes
每周胰岛素与2型糖尿病的治疗负担
J.R. Ingelfinger and C.J. Rosen
N Engl J Med; July 24, 2025; 393(4):401-402
15
Ivermectin against Malaria — Good News in Bad Times
伊维菌素抗疟疾——艰难时期的好消息
R.W. Steketee
N Engl J Med; July 24, 2025; 393(4):402-404
CLINICAL DECISIONS(临床决策)
16
Statin Therapy for Children
儿童他汀类药物治疗
H.K. Marwah, I.K. Luirink , and M. Mietus-Snyder
N Engl J Med; July 24, 2025; 393(4):405-407
CORRESPONDENCE(通信)
17
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
奥比妥珠单抗治疗活动性狼疮性肾炎的疗效和安全性
N Engl J Med; July 24, 2025; 393(4):408-410
18
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Lepodisiran -一种靶向脂蛋白(A)的长效干扰性小RNA
N Engl J Med; July 24, 2025; 393(4):411-412
19
BCG Revaccination to Prevent Tuberculosis
卡介苗复种预防结核病
N Engl J Med; July 24, 2025; 393(4):412-413
20
Evolving Epidemiology of Mpox in Africa in 2024
2024年非洲猴痘流行病学演变
N Engl J Med; July 24, 2025; 393(4):414
21
Enteral Nutrition in Hospitalized Adults
住院成人肠内营养
N Engl J Med; July 24, 2025; 393(4):415-416
N Engl J Med[Jour] AND 393[volume] AND 5[issue]
新英格兰医学杂志 393卷5期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Revised Recommendations for Covid-19 Vaccines — U.S. Vaccination Policy under Threat
Covid-19疫苗修订建议——美国疫苗接种政策受到威胁
J.L. Schwartz
N Engl J Med; July 31, 2025; 393(5):417-419
2
Public Policies, Social Narratives, and Population Health
公共政策、社会叙事与人口健康
A.S. Venkataramani , P.S. Tamber , and A. Iton
N Engl J Med; July 31, 2025; 393(5):419-421
3
Into the Valley of the Sick
进入病痛的之谷
S. Wesloh
N Engl J Med; July 31, 2025; 393(5):421-423
4
Interactive Perspective: Human Papillomavirus and Cancer
互动视角：人类乳头瘤病毒与癌症
J.R. Barzilay and Others
N Engl J Med; July 31, 2025; 393(5):e6
ORIGINAL ARTICLES(论著)
5
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
可测量的残留疾病–指导新诊断的骨髓瘤治疗
A. Perrot and Others
N Engl J Med; July 31, 2025; 393(5):425-437
6
Mitochondrial Donation and Preimplantation Genetic Testing for mtDNA Disease
线粒体捐献和植入前mtDNA疾病基因检测
L.A. Hyslop and Others
N Engl J Med; July 31, 2025; 393(5):438-449
7
A Randomized Trial of Acute Normovolemic Hemodilution in Cardiac Surgery
心脏手术中急性等容血稀释的随机试验
F. Monaco and Others
N Engl J Med; July 31, 2025; 393(5):450-460
8
Brief Report: Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease
简要报告：线粒体捐赠在mtDNA疾病的生殖保健途径
R. McFarland and Others
N Engl J Med; July 31, 2025; 393(5):461-468
9
Brief Report: Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling
简要报告：通过恢复t细胞受体信号传导来解决鳞状细胞癌
P. Ye and Others
N Engl J Med; July 31, 2025; 393(5):469-478
REVIEW ARTICLE(综述文章)
10
Motor Vehicle Crash Prevention
预防机动车辆碰撞
S.G. Klauer and Z.R. Doerzaph
N Engl J Med; July 31, 2025; 393(5):479-486
IMAGES IN CLINICAL MEDICINE(临床医学影像)
11
Spontaneous Intracranial Hypotension
自发性颅内低血压
S.B. Owais and Y. Kianirad
N Engl J Med; July 31, 2025; 393(5):487
12
Spiderweb-like Vessels in Retinopathy of Prematurity
早产儿视网膜病变中的蜘蛛网状血管
X. Zhao and G. Zhang
N Engl J Med; July 31, 2025; 393(5):e7
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马赛诸塞州总医院病例记录）
13
Case 22-2025: A 19-Year-Old Woman with Seizurelike Activity and Odd Behaviors
案例22-2025：一名19岁女性出现癫痫样活动和怪异行为
J.A. Restrepo and Others
N Engl J Med; July 31, 2025; 393(5):488-496
EDITORIALS(社论)
14
Opening the Door to Tailored Treatment in Newly Diagnosed Multiple Myeloma
开启新诊断多发性骨髓瘤个性化治疗的大门
P.G. Richardson , N.C. Munshi , and D.L. Longo
N Engl J Med; July 31, 2025; 393(5):498-500
15
Reducing the Risks of Mitochondrial Disease in Children
降低儿童线粒体疾病的风险
R. Lovell-Badge
N Engl J Med; July 31, 2025; 393(5):500-503
16
Science behind the Study: Advances in Preventing Transmission of Mitochondrial DNA Diseases
研究背后的科学：预防线粒体DNA疾病传播的进展
J. Steffann
N Engl J Med; July 31, 2025; 393(5):503-507
MEDICINE AND SOCIETY(医学与社会)
17
Reform and Remedy for Imprecision and Inequity — Ending the Race-Based Evaluation of Occupational Pulmonary Impairment
改革与修正——终结基于种族的职业性肺功能障碍评估
R. Khazanchi and Others
N Engl J Med; July 31, 2025; 393(5):508-514
CORRESPONDENCE(通信)
18
Phase 2a Study of Baxdrostat in Primary Aldosteronism
巴司他治疗原发性醛固酮增多症的2a期研究
N Engl J Med; July 31, 2025; 393(5):515-518
19
Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation
脉冲场或低温球囊消融治疗阵发性心房颤动
N Engl J Med; July 31, 2025; 393(5):518-520
N Engl J Med[Jour] AND 393[volume] AND 6[issue]
新英格兰医学杂志 393卷6期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
The Corporatization of U.S. Health Care: A Gilded Age for Patients? The Broken Promises of Profit-Driven Medicine
美国医疗保健公司化：病人的镀金时代？利润驱动的医药破碎的承诺
N. Tomes
N Engl J Med;August 7,2025;393(6):521-524
2
Lead Contamination in Milwaukee Schools — The Latest Episode in an Ongoing Toxic Pandemic
密尔沃基学校的铅污染——正在进行的毒性大流行的最新事件
M.S. Kanarek
N Engl J Med;August 7,2025;393(6):524-526
3
Training Health Communicators — The Need for a New Approach
培训健康传播者——需要一种新的方法
K. Panthagani and Others
N Engl J Med;August 7,2025;393(6):526-529
4
ER and Me
急诊室和我
E. Rourke
N Engl J Med;August 7,2025;393(6):529-531
ORIGINAL ARTICLES(论著)
5
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
芬尼酮联合恩格列净治疗慢性肾病和2型糖尿病
R. Agarwal and Others
N Engl J Med;August 7,2025;393(6):533-543
6
Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague
环丙沙星与氨基糖苷-环丙沙星治疗黑死病
R.V. Randremanana and Others
N Engl J Med;August 7,2025;393(6):544-555
7
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Vepdegestrant：一种用于晚期乳腺癌的PROTAC雌激素受体降解剂
M. Campone and Others
N Engl J Med;August 7,2025;393(6):556-568
8
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
一线用药卡米兹斯特兰治疗新发ESR1突变的晚期乳腺癌
F.-C. Bidard and Others
N Engl J Med;August 7,2025;393(6):569-580
REVIEW ARTICLE(综述)
9
Testosterone Treatment in Middle-Aged and Older Men with Hypogonadism
中老年低促性腺激素性腺功能减退症患者的睾酮治疗
S. Bhasin and P.J. Snyder
N Engl J Med;August 7,2025;393(6):581-591
IMAGES IN CLINICAL MEDICINE(临床医学影像)
10
E-Cigarette– or Vaping-Associated Lung Injury
电子烟–或吸电子烟–相关肺损伤
M.Z. Roslly and S.A. Syed Rozhan
N Engl J Med;August 7,2025;393(6):592
11
Crusted Scabies
陈年的疥疮
Y.-J. Sun and H. Gong
N Engl J Med;August 7,2025;393(6):e8
CLINICAL PROBLEM-SOLVING(临床问题解决)
12
Gasping for Strength
喘息求生
D. Zarhin , H. Kolb , and A. Gadoth
N Engl J Med;August 7,2025;393(6):593-599
EDITORIALS(社论)
13
Combination Therapy for Chronic Kidney Disease and Type 2 Diabetes — A Promising Prelude
慢性肾病和2型糖尿病的联合治疗——充满希望的前奏
C. Zoccali and F. Mallamaci
N Engl J Med;August 7,2025;393(6):601-602
14
Chipping Away at an Old Foe
逐步击破旧敌
P. Mead
N Engl J Med;August 7,2025;393(6):603-604
15
Science behind the Study: Degradation of the Estrogen Receptor in Breast Cancer
研究背后的科学：乳腺癌中雌激素受体的降解
D.P. McDonnell
N Engl J Med;August 7,2025;393(6):604-608
MEDICINE AND SOCIETY(医学与社会)
16
Restoring the Infant Mortality Rate as a Measure of Societal Health and Well-Being
恢复将婴儿死亡率作为衡量社会健康和福祉的一项指标
E.A. Harrison , U. Ndulue , and B.O. Ojikutu
N Engl J Med;August 7,2025;393(6):609-614
CORRESPONDENCE(通信)
17
Xenon — Propelling Climbers to the Summits of the World’s Highest Mountains?
氙气—推动登山者登顶世界最高的山脉？
N Engl J Med;August 7,2025;393(6):615-616
18
Daratumumab for High-Risk Smoldering Multiple Myeloma
达雷妥尤单抗用于高危沉默型多发性骨髓瘤
N Engl J Med;August 7,2025;393(6):616-617
19
A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
2型糖尿病患者自动胰岛素输送的随机试验
N Engl J Med;August 7,2025;393(6):617-619
20
Enhanced CAR T-Cell Therapy for Relapsed Lymphoma
增强型CAR T细胞疗法治疗复发性淋巴瘤
N Engl J Med;August 7,2025;393(6):619-620
21
Malaria
疟疾
N Engl J Med;August 7,2025;393(6):620-621
22
Neonatal Fc Receptor — Biology and Therapeutics
新生儿Fc受体——生物学与治疗
N Engl J Med;August 7,2025;393(6):621-623
NEngl J Med[Jour] AND 393[volume] AND 7[issue]
新英格兰医学杂志 393卷7期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Dismantling Public Health Infrastructure, Endangering American Lives
拆除公共卫生基础设施危及美国人的生命
T.R. Frieden
N Engl J Med;August 14,2025;393(7):625-627
2
Progress Lost — The Unraveling of Medicaid and the Affordable Care Act
停滞不前——医疗补助和《平价医疗法案》的瓦解
J. Oberlander
N Engl J Med;August 14,2025;393(7):628-629
3
The Resurgence of Private Law in American Health Care
美国医疗保健私法的复兴
C. Robertson and W.N. Epstein
N Engl J Med;August 14,2025;393(7):630-631
4
The Serendipitous Dance between Life and Death
生与死之间的偶然之舞
A. Zorigtbaatar
N Engl J Med;August 14,2025;393(7):632-633
ORIGINAL ARTICLES(论著)
5
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Cagrilintide和Semaglutide联合应用于超重或肥胖的成人
W.T. Garvey and Others
N Engl J Med;August 14,2025;393(7):635-647
6
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Cagrilintide–Semaglutide在超重或肥胖和2型糖尿病成人中的应用
M.J. Davies and Others
N Engl J Med;August 14,2025;393(7):648-659
7
A Crossover Trial of Hospital-Wide Lactated Ringer’s Solution versus Normal Saline
医院范围内的乳酸林格氏溶液与生理盐水的交叉试验
L. McIntyre and Others
N Engl J Med;August 14,2025;393(7):660-670
8
Risdiplam in Presymptomatic Spinal Muscular Atrophy
Risdiplam治疗亚临床脊髓性肌萎缩症
R.S. Finkel and Others
N Engl J Med;August 14,2025;393(7):671-682
REVIEW ARTICLE(综述)
9
Metabolic Dysfunction–Associated Steatotic Liver Disease
代谢功能障碍相关脂肪性肝病
G. Targher , L. Valenti , and C.D. Byrne
N Engl J Med;August 14,2025;393(7):683-698
IMAGES IN CLINICAL MEDICINE(临床医学影像)
10
Snowman Sign in Pituitary Macroadenoma
垂体巨腺瘤的雪人征
Y. Zhou and W. Weng
N Engl J Med;August 14,2025;393(7):699
11
Ocular Gnathostomiasis
眼型囊尾蚴病
S. Karkhur and A. Gupta
N Engl J Med;August 14,2025;393(7):e9
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马萨诸塞州总医院病例记录)
12
Case 23-2025: A 28-Year-Old Woman with Respiratory Failure and Abnormal Chest Imaging
病例23-2025：一例28岁女性，呼吸衰竭伴胸部影像异常
W.J. Janssen and Others
N Engl J Med;August 14,2025;393(7):700-710
EDITORIALS(社论)
13
Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care
扩展肥胖和糖尿病的治疗目标工具箱
C.M. Hales
N Engl J Med;August 14,2025;393(7):712-714
14
Science behind the Study: Presymptomatic Treatment of a Genetic Disease with a Small-Molecule Drug
研究背后的科学：小分子药物在遗传性疾病亚临床阶段中的治疗
C.J. Sumner
N Engl J Med;August 14,2025;393(7):714-717
15
Reviewers for the Journal, January–June 2025
本杂志2025年1月至6月的审稿人
E.J. Rubin
N Engl J Med;August 14,2025;393(7):718
CLINICAL DECISIONS(临床决策)
16
Managing Obesity
肥胖治疗
C.P. Kotanidis , A.M. Lincoff , and S.A. Shikora
N Engl J Med;August 14,2025;393(7)::719-721
CORRESPONDENCE(通信)
17
A Naturally Occurring Gain-of-Function Mutation in Factor VIII
因子VIII中自然发生的功能获得突变
N Engl J Med;August 14,2025;393(7):722-724
18
Oral Semaglutide and Cardiovascular Outcomes
口服司美格鲁肽与心血管预后
N Engl J Med;August 14,2025;393(7):724-725
19
Lorundrostat Efficacy and Safety in Uncontrolled Hypertension
Lorundrostat在未控制的高血压中的疗效和安全性
N Engl J Med;August 14,2025;393(7):725-727
20
Cancer of Unknown Primary Site
原发部位不明的癌症
N Engl J Med;August 14,2025;393(7):727-728
N Engl J Med[Jour] AND 393[volume] AND 8[issue]
新英格兰医学杂志 393卷 8期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Preventive Care at the Supreme Court
最高法院谈预防性医疗
N. Bagley
N Engl J Med; Aug 21/28, 2025; 393(8)：729-731
2
Regulating Private Equity in Health Care — The Massachusetts Model
医疗保健领域私募股权的监管——马萨诸塞模式
T.C. Tsai , G.S. Meyer , and D. Blumenthal
N Engl J Med; Aug 21/28, 2025; 393(8)：731-733
3
Reforming the Prescription Drug User Fee Program
改革处方药用户费用计划
T.J. Ziaks and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：734-736
4
The Consultant
顾问视角
T. Adzemovic
N Engl J Med; Aug 21/28, 2025; 393(8)：736-739
ORIGINAL ARTICLES（论著）
5
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
纳武利尤单抗联合化疗新辅助治疗肺癌的总生存期
P.M. Forde and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：741-752
6
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
艾琳扎奈坦特用于乳腺癌内分泌治疗引起的血管舒缩症状
F. Cardoso and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：753-763
7
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
吸入莫格拉斯汀治疗自身免疫性肺泡蛋白沉积症的3期试验
B.C. Trapnell and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：764-773
8
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
西米普利单抗辅助治疗对比安慰剂用于高危皮肤鳞状细胞癌
D. Rischin and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：774-785
REVIEW ARTICLE（综述）
9
Medical Education: Educational Strategies for Clinical Supervision of Artificial Intelligence Use
医学教育：人工智能应用临床监督的教育策略
R.-E.E. Abdulnour , B. Gin , and C.K. Boscardin
N Engl J Med; Aug 21/28, 2025; 393(8)：786-797
IMAGES IN CLINICAL MEDICINE（临床医学影像）
10
Paraganglioma in the Organ of Zuckerkandl
颈动脉体旁器官副神经节瘤
R. Cohen and P. Hammill
N Engl J Med; Aug 21/28, 2025; 393(8)：798
11
Abdominojugular Reflux Test
腹颈静脉回流试验
S. Bent and G. Dhaliwal
N Engl J Med; Aug 21/28, 2025; 393(8)：e10
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
12
Case 24-2025: A 32-Year-Old Woman with Fatigue and Myalgias
2025年第24例病例：一例32岁女性，疲劳伴肌痛
D.G. Kwolek and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：799-807
EDITORIALS（社论）
13
Redefining Lung Cancer Therapy — A Long-Awaited Shift in Strategy
重新定义肺癌治疗——期待已久的策略转变
V. Calvo
N Engl J Med; Aug 21/28, 2025; 393(8)：809-810
14
Menopausal Symptom Management in Breast Cancer Survivors — A Promising New Option
乳腺癌幸存者的更年期症状管理——一种有前景的新选择
A.H. Partridge
N Engl J Med; Aug 21/28, 2025; 393(8)：810-812
15
Science behind the Study: GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis
研究背后的科学：GM-CSF在自身免疫性肺泡蛋白沉积症中的作用
J.F. Seymour
N Engl J Med; Aug 21/28, 2025; 393(8)：812-816
SOUNDING BOARD（讨论专区）
16
The Path Forward for Vaccine Policy in the United States
美国疫苗政策的未来之路
H.Y. Chu and Others
N Engl J Med; Aug 21/28, 2025; 393(8)：817-822
CORRESPONDENCE（读者来信）
17
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy
抗BCMA CAR-T细胞治疗后CAR+ T细胞淋巴瘤的靶向治疗
N Engl J Med; Aug 21/28, 2025; 393(8)：823-825
18
Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
司美格鲁肽治疗代谢相关脂肪性肝炎
N Engl J Med; Aug 21/28, 2025; 393(8)：826-828
19
Omitting Nodal Irradiation after Nodes Clear
淋巴结清除后省略淋巴结放疗
N Engl J Med; Aug 21/28, 2025; 393(8)：828-829
20
AAV Gene Therapy in Severe Hemophilia B
严重血友病B的腺相关病毒（AAV）基因治疗
N Engl J Med; Aug 21/28, 2025; 393(8)：829-830
21
Screening for Prostate Cancer with a Polygenic Risk Score
基于多基因风险评分的前列腺癌筛查
N Engl J Med; Aug 21/28, 2025; 393(8)：831-832
CORRECTION（更正）
22
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
恩扎卢胺改善生化复发前列腺癌的预后
N Engl J Med; Aug 21/28, 2025; 393(8)：832
N Engl J Med[Jour] AND 393[volume] AND 9[issue]
新英格兰医学杂志 393卷 9期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: The Corporatization Deal — Health Care, Investors, and the Profit Priority
美国医疗保健的企业化：企业化交易——医疗保健、投资者与利润优先
A. Chandra and M. Shepard
N Engl J Med; Sep 4, 2025; 393(9)：833-835
2
Advancing Physician-Scientist Training in China — Challenges, Gaps, and Future Directions
推进中国医师科学家培养——挑战、差距与未来方向
P. Li and Others
N Engl J Med; Sep 4, 2025; 393(9)：836-838
3
The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally
中国药物创新的崛起——对美国及全球患者药物可及性的影响
K.N. Vokinger , G. Li , and O.J. Wouters
N Engl J Med; Sep 4, 2025; 393(9)：839-841
ORIGINAL ARTICLES（论著）
4
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
每月一次的马里德巴特卡弗拉鲁肽治疗肥胖——一项2期试验
A.M. Jastreboff and Others
N Engl J Med; Sep 4, 2025; 393(9)：843-857
5
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
干细胞衍生的完全分化胰岛用于治疗1型糖尿病
T.W. Reichman and Others
N Engl J Med; Sep 4, 2025; 393(9)：858-868
6
One Dose versus Three Doses of Benzathine Penicillin G in Early Syphilis
早期梅毒治疗中苄星青霉素G单次剂量与三次剂量的对比
E.W. Hook III and Others
N Engl J Med; Sep 4, 2025; 393(9)：869-878
7
Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia
单克隆抗体在肝素诱导的血小板减少症发病机制中的作用
J. Treverton and Others
N Engl J Med; Sep 4, 2025; 393(9)：879-886
8
Brief Report: Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression
简短报告：无需免疫抑制的移植同种异体β细胞存活情况
P.-O. Carlsson and Others
N Engl J Med; Sep 4, 2025; 393(9)：887-894
REVIEW ARTICLE（综述）
9
Management of Acute Type B Aortic Dissection
急性B型主动脉夹层的管理
F.F. Mussa and P. Kougias
N Engl J Med; Sep 4, 2025; 393(9)：895-905
VIDEOS IN CLINICAL MEDICINE（临床医学视频）
10
Ultrasound-Guided Paracentesis
超声引导下腹腔穿刺术
A. Kumar and Others
N Engl J Med; Sep 4, 2025; 393(9)：e11
IMAGES IN CLINICAL MEDICINE（临床医学图像）
11
Popeye Sign in Transthyretin Amyloidosis
转甲状腺素蛋白淀粉样变性中的“大力水手”征
S. Kurisu and H. Fujiwara
N Engl J Med; Sep 4, 2025; 393(9)：906
12
Radiation Pneumonitis
放射性肺炎
M. Peters and P. Jeene
N Engl J Med; Sep 4, 2025; 393(9)：e12
13
Hutchinson’s Sign in Subungual Melanoma In Situ
甲下原位黑色素瘤的Hutchinson征
M. Pasch and J. Tutein Nolthenius
N Engl J Med; Sep 4, 2025; 393(9)：e13
CLINICAL PROBLEM-SOLVING（疑难杂症求解探微）
14
A Fruitful Workup
卓有成效的检查过程
N. Jain and Others
N Engl J Med; Sep 4, 2025; 393(9)：907-914
EDITORIALS（社论）
15
A Tale of Two Diseases
两种疾病的故事
M.L. Collazo-Clavell
N Engl J Med; Sep 4, 2025; 393(9)：916-917
16
Science behind the Study: Replacement of Beta Cells for Type 1 Diabetes
研究背后的科学：1型糖尿病的β细胞替代
K.C. Herold and J.S. Pober
N Engl J Med; Sep 4, 2025; 393(9)：917-921
17
Antiquated Tools to Fight an Ancient Foe
用陈旧工具对抗古老敌人
L.A. Barbee and L.H. Bachmann
N Engl J Med; Sep 4, 2025; 393(9)：921-923
CORRESPONDENCE（通信）
18
Fulminant Viral Myocarditis Associated with Thogotovirus
与托高托病毒相关的暴发性病毒性心肌炎
N Engl J Med; Sep 4, 2025; 393(9)：924-926
19
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
奥比西特拉匹在高心血管风险患者中的安全性与有效性
N Engl J Med; Sep 4, 2025; 393(9)：926-928
20
Porcine Xenotransplantation in End-Stage Kidney Disease
终末期肾病中的猪异种移植
N Engl J Med; Sep 4, 2025; 393(9)：929-931
21
Malnutrition in Older Adults
老年人营养不良
N Engl J Med; Sep 4, 2025; 393(9)：931-933
22
Generative AI in Medicine
医学中的生成式人工智能
N Engl J Med; Sep 4, 2025; 393(9)：933-935
N Engl J Med[Jour] AND 393[volume] AND 10[issue]
新英格兰医学杂志 393卷10期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Efforts toward Equity: Caring for Patients with Intellectual or Developmental Disabilities —A Curriculum for Residents
迈向公平的努力：照顾有智力或发育障碍的患者——住院医师培训课程
L. Clarke and Others
N Engl J Med; Sep 11, 2025; 393(10)：937-939
2
Efforts toward Equity: Diaper Need —An Underrecognized Social Driver of Health
迈向公平的努力：尿布需求——一个未被充分认识的社会健康驱动因素
W. Berry , J. Bonville , and S.D. Blatt
N Engl J Med; Sep 11, 2025; 393(10)：939-940
3
Efforts toward Equity: Improving Care Coordination for Indigenous Patients with Cancer
迈向公平的努力：改善对患癌原住民患者的护理协调
A.E. Janitz and Others
N Engl J Med; Sep 11, 2025; 393(10)：940-942
4
Health and Medical Research Funding in a Divided America— How to Increase Support
分裂的美国在卫生与医学研究方面的资金投入——如何增加支持
R.J. Blendon , J.M. Benson , and N.B. Le
N Engl J Med; Sep 11, 2025; 393(10)：942-945
5
The End of Days
末日终结
I.Thomas
N Engl J Med; Sep 11, 2025; 393(10)：945-947
ORIGINAL ARTICLES（论著）
6
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
Aficamten或美托洛尔单药治疗梗阻性肥厚型心肌病
P. Garcia-Pavia and Others
N Engl J Med; Sep 11, 2025; 393(10)：949-960
7
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Mavacamten治疗有症状的非梗阻性肥厚型心肌病
M.Y. Desai and Others
N Engl J Med; Sep 11, 2025; 393(10)：961-972
8
Multidomain Rehabilitation for Older Patients with Myocardial Infarction
针对老年心肌梗死患者的多领域康复治疗
E. Tonet and Others
N Engl J Med; Sep 11, 2025; 393(10)：973-982
9
Marburg Virus Disease in Rwanda, 2024 —Public Health and Clinical Responses
2024年卢旺达的马尔堡病毒病——公共卫生与临床应对措施
S. Nsanzimana and Others
N Engl J Med; Sep 11, 2025; 393(10)：983-993
SPECIAL ARTICLE（专题论著）
10
Medications for Opioid Use Disorder in County Jails —Outcomes after Release
县监狱中阿片类药物使用障碍的治疗药物——释放后的结果
P.D. Friedmann and Others
N Engl J Med; Sep 11, 2025; 393(10)：994-1003
REVIEW ARTICLE（综述）
11
Hypertrophic Cardiomyopathy
肥厚型心肌病
E. Braunwald
N Engl J Med; Sep 11, 2025; 393(10)：1004-1015
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Pityriasis Rosea
玫瑰糠疹
E.A. Rallis and C. Verros
N Engl J Med; Sep 11, 2025; 393(10)：1016
13
Acute Epididymo-orchitis in IgA Vasculitis
IgA血管炎伴急性附睾- 睾丸炎
S. Pariha and C. Hanna
N Engl J Med; Sep 11, 2025; 393(10)：e14
14
Ruptured Pulmonary Hydatid Cyst
肺包虫囊肿破裂
Y. Aydin and H. Ogul
N Engl J Med; Sep 11, 2025; 393(10)：e15
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
15
Case 25-2025: A 93-Year-Old Woman with Dyspnea and Fatigue
2025年第25例病例：一例93岁女性，呼吸困难伴疲劳
S.V. Arnold and Others
N Engl J Med; Sep 11, 2025; 393(10)：1017-1024
EDITORIAL（社论）
16
Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions
扩大肌球蛋白抑制在肥厚型心肌病中的作用——两种疾病的故事
A.V. Ambardekar
N Engl J Med; Sep 11, 2025; 393(10)：1026-1028
MEDICINE AND SOCIETY（医学与社会）
17
The Race-Correction Debates —Progress, Tensions, and Future Directions
种族校正争议——进展、紧张局势和未来方向
D.A. Vyas , L.G. Eisenstein , and D.S. Jones
N Engl J Med; Sep 11, 2025; 393(10)：1029-1036
CORRESPONDENCE（读者来信）
18
Long-Term Outcomes of the DanGer Shock Trial
DanGer休克试验的长期结果
N Engl J Med; Sep 11, 2025; 393(10)：1037-1038
19
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Efruxifermin治疗MASH所致的代偿性肝硬化
N Engl J Med; Sep 11, 2025; 393(10)：1038-1039
20
Once-Weekly Mazdutide in Obesity or Overweight
每周一次Mazdutide治疗肥胖或超重
N Engl J Med; Sep 11, 2025; 393(10)：1040
N Engl J Med[Jour] AND 393[volume] AND 11[issue]
新英格兰医学杂志 393卷11期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Reducing Tobacco Use Worldwide: Integrating Pharmacotherapy into Tobacco Control in Low- and Middle-Income Countries — A Critical Need
全球范围内减少烟草使用：将药物治疗纳入中低收入国家烟草控制——一项迫切需求
N.A. Rigotti , N. Walker , and A.S. Amer Nordin
N Engl J Med; Sep 18, 2025; 393(11)：1041-1044
2
Protecting Medicaid Enrollees with Chronic Conditions amid Work Requirements
在工作要求下保护患有慢性病的医疗补助计划（Medicaid）参保人
J.Z. Ayanian
N Engl J Med; Sep 18, 2025; 393(11)：1044-1046
3
Ultraprocessed Food on an Ultrafast Track
超加工食品驶入超速发展轨道
D.S. Ludwig
N Engl J Med; Sep 18, 2025; 393(11)：1046-1049
4
The Consequences of Silencing the “Voice of CDC”
“美国疾控中心之声”被消音的后果
S.A. Rasmussen and Others
N Engl J Med; Sep 18, 2025; 393(11)：e16
5
Medicaid on the Chopping Block
医疗补助计划（Medicaid）面临削减
E. Park
N Engl J Med; Sep 18, 2025; 393(11)：e17
ORIGINAL ARTICLES（论著）
6
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
低剂量阿司匹林用于PI3K突变的局限性结直肠癌
A. Martling and Others
N Engl J Med; Sep 18, 2025; 393(11)：1051-1064
7
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Orforglipron（一种口服小分子GLP-1受体激动剂）用于早期2型糖尿病
J. Rosenstock and Others
N Engl J Med; Sep 18, 2025; 393(11)：1065-1076
8
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
口服司美格鲁肽25 mg用于超重或肥胖成人
S. Wharton and Others
N Engl J Med; Sep 18, 2025; 393(11)：1077-1087
9
Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation
比例辅助通气以缩短机械通气时间
K.J. Bosma and Others
N Engl J Med; Sep 18, 2025; 393(11)：1088-1103
REVIEW ARTICLE（综述）
10
Tumor Lysis Syndrome
肿瘤溶解综合征
R.G. Bociek and M. Lunning
N Engl J Med; Sep 18, 2025; 393(11)：1104-1116
IMAGES IN CLINICAL MEDICINE（临床医学影像）
11
Subcutaneous Panniculitis-like T-Cell Lymphoma
皮下脂膜炎样T细胞淋巴瘤
S. Okada and M. Nishikubo
N Engl J Med; Sep 18, 2025; 393(11)：1117
12
Primary Varicella Infection
原发性水痘感染
O. van Not and D. Rauwerdink
N Engl J Med; Sep 18, 2025; 393(11)：e18
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
13
Case 26-2025: An 11-Year-Old Girl with Chest Pain and Bone and Liver Lesions
2025年第26例病例：一例11岁女孩，胸痛伴骨和肝脏病变
L.P. Carter and Others
N Engl J Med; Sep 18, 2025; 393(11)：1118-1127
EDITORIALS（社论）
14
Reducing Tobacco Use Worldwide — A New Perspective Series
全球减少烟草使用——新观点系列
N.A. Rigotti and Others
N Engl J Med; Sep 18, 2025; 393(11)：1129-1130
15
An Aspirin a Day for Improved Colorectal Cancer Outcomes
每日一片阿司匹林以改善结直肠癌预后
R.M. Goldberg and J.A. Meyerhardt
N Engl J Med; Sep 18, 2025; 393(11)：1131-1132
16
Mimicking Complex Receptor Actions with Small(ish) Molecules
用小（型）分子模拟复杂受体作用
D.B. Lowe
N Engl J Med; Sep 18, 2025; 393(11)：1133-1134
CORRESPONDENCE（通信）
17
Introduction of Mpox Virus Clade Ib into the Republic of the Congo
猴痘病毒Ib分支传入刚果共和国
N Engl J Med; Sep 18, 2025; 393(11)：1135-1137
18
Perioperative Pembrolizumab in Head and Neck Cancer
围手术期帕博利珠单抗用于头颈癌
N Engl J Med; Sep 18, 2025; 393(11)：1138-1139
19
Ondansetron after ED Visits in Children with Gastroenteritis
儿童胃肠炎急诊就诊后使用昂丹司琼
N Engl J Med; Sep 18, 2025; 393(11)：1139-1141
20
Navigating the Discontinuity Crisis in Medical Education
应对医学教育中的断层危机
N Engl J Med; Sep 18, 2025; 393(11)：1141-1143
21
Fetal Hereditary Thrombotic Thrombocytopenic Purpura
胎儿遗传性血栓性血小板减少性紫癜
N Engl J Med; Sep 18, 2025; 393(11)：1143-1144
N Engl J Med[Jour] AND 393[volume] AND 12[issue]
新英格兰医学杂志 393卷12期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Structural and Scientific Racism, Science, and Health — Evidence versus Ideology
结构性与科学层面的种族主义、科学与健康——证据与意识形态之争
N. Krieger and M.T. Bassett
N Engl J Med; Sep 25, 2025; 393(12)：1145-1148
2
From Health to Wealth — Reframing Global Aid through the Gates Foundation’s Final Chapter
从健康到财富——通过盖茨基金会的终章重新构建全球援助框架
S. Phillips
N Engl J Med; Sep 25, 2025; 393(12)：1148-1151
3
Dr. Kolhouse and the Cowboy
科尔豪斯博士与牛仔
M. Earnest
N Engl J Med; Sep 25, 2025; 393(12)：1151-1153
ORIGINAL ARTICLES（论著）
4
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction
地高辛用于射血分数降低的心力衰竭患者
U. Bavendiek and Others
N Engl J Med; Sep 25, 2025; 393(12)：1155-1165
5
Apixaban for Extended Treatment of Provoked Venous Thromboembolism
阿哌沙班用于诱因性静脉血栓栓塞症的延长治疗
G. Piazza and Others
N Engl J Med; Sep 25, 2025; 393(12)：1166-1176
6
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
基于可测量残留病灶指导的慢性淋巴细胞白血病治疗
T. Munir and Others
N Engl J Med; Sep 25, 2025; 393(12)：1177-1190
7
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke
卒中静脉溶栓后早期输注替罗非班
C. Tao and Others
N Engl J Med; Sep 25, 2025; 393(12)：1191-1201
REVIEW ARTICLE（综述）
8
Medical Education: Advancing Diagnostic Excellence through Medical Education in Diagnostic Equity
医学教育：通过诊断公平性医学教育推进诊断卓越
D.M. Connor , M.L. Lypson , and C.M. Gonzalez
N Engl J Med; Sep 25, 2025; 393(12)：1202-1214
IMAGES IN CLINICAL MEDICINE（临床医学影像）
9
Systemic Mastocytosis
系统性肥大细胞增多症
L. Neves da Silva and A.M. Monteiro
N Engl J Med; Sep 25, 2025; 393(12)：1215
10
Doxycycline-Induced Phototoxicity
多西环素诱导的光毒性反应
G. Boyd and C. Cheng
N Engl J Med; Sep 25, 2025; 393(12)：e19
INTERACTIVE MEDICAL CASE（互动式医学病例）
11
A Fizzy Fix
气泡疗法
M.A. Crane and Others
N Engl J Med; Sep 25, 2025; 393(12)：e20
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
12
Case 27-2025: A 53-Year-Old Man with Embolic Stroke and Left Ventricular Apical Aneurysm
2025年第27例病例：一例53岁男性，患有栓塞性卒中及左心室心尖部动脉瘤
G.C. Stewart and Others
N Engl J Med; Sep 25, 2025; 393(12)：1216-1225
EDITORIALS（社论）
13
Digitoxin — A Reminder for Digoxin
地高辛——对洋地黄的提醒
M.A. Pfeffer
N Engl J Med; Sep 25, 2025; 393(12)：1227-1228
14
Art within Evidence — Balancing Anticoagulant Duration in VTE Care
证据中的艺术——平衡静脉血栓栓塞症护理中的抗凝时长
N.A. Zakai
N Engl J Med; Sep 25, 2025; 393(12)：1229-1230
CLINICAL IMPLICATIONS OF BASIC RESEARCH（基础研究的临床意义）
15
Transformative Research in Cystic Fibrosis
囊性纤维化的变革性研究
E.J. Sorscher
N Engl J Med; Sep 25, 2025; 393(12)：1231-1234
16
Surprisingly Complex Assemblies from Low-Complexity Domains
来自低复杂度结构域的惊人复杂组装
T. Mittag
N Engl J Med; Sep 25, 2025; 393(12)：1235-1238
CORRESPONDENCE（通信）
17
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis
CD19嵌合抗原受体T细胞疗法治疗多重耐药性溃疡性结肠炎
N Engl J Med; Sep 25, 2025; 393(12)：1239-1241
18
Nonoperative Management of Mismatch Repair–Deficient Tumors
错配修复缺陷肿瘤的非手术治疗
N Engl J Med; Sep 25, 2025; 393(12)：1241-1243
19
Cerebral Embolic Protection during TAVI
经导管主动脉瓣置换术中的脑栓塞保护
N Engl J Med; Sep 25, 2025; 393(12)：1243-1245
20
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates
心血管危险因素对终生估计的全球影响
N Engl J Med; Sep 25, 2025; 393(12)：1245-1248
N Engl J Med[Jour] AND 393[volume] AND 13[issue]
新英格兰医学杂志 393卷13期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: Insight into Corporate Governance — What Motivates Hospitals and Delivery Systems
美国医疗保健的企业化：企业治理洞察——医院和医疗交付系统的动机何在
S. Lipstein
N Engl J Med; Oct 2, 2025; 393(13)：1249-1251
2
The Risks of Pharmaceutical Tariffs for Generic Drug Availability
药品关税对仿制药供应的风险
T.J. Hwang , Q.-D. Trinh , and K.N. Vokinger
N Engl J Med; Oct 2, 2025; 393(13)：1252-1253
3
Goals for Opioid Use Disorder Medications — Protection, Remission, and Recovery
阿片类药物使用障碍治疗药物的目标——保护、缓解和康复
A.T. McLellan and N.D. Volkow
N Engl J Med; Oct 2, 2025; 393(13)：1253-1255
ORIGINAL ARTICLES（论著）
4
Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis
伴有胃肠炎的严重急性营养不良的静脉补液治疗
K. Maitland and Others
N Engl J Med; Oct 2, 2025; 393(13)：1257-1268
5
Medical Imaging and Pediatric and Adolescent Hematologic Cancer Risk
医学影像与儿童和青少年血液系统癌症风险
R. Smith-Bindman and Others
N Engl J Med; Oct 2, 2025; 393(13)：1269-1278
6
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
使用针对APOC3的奥列扎森治疗中度高甘油三酯血症
B.A. Bergmark and Others
N Engl J Med; Oct 2, 2025; 393(13)：1279-1291
7
Clesrovimab for Prevention of RSV Disease in Healthy Infants
克莱斯罗维玛布预防健康婴儿呼吸道合胞病毒疾病
H.J. Zar and Others
N Engl J Med; Oct 2, 2025; 393(13)：1292-1303
8
Home-Based Care for Hypertension in Rural South Africa
南非农村地区高血压的家庭护理
M.J. Siedner and Others
N Engl J Med; Oct 2, 2025; 393(13)：1304-1314
REVIEW ARTICLE（综述）
9
Monoclonal Gammopathy of Undetermined Significance
意义未定的单克隆丙种球蛋白病
S.V. Rajkumar and S. Kumar
N Engl J Med; Oct 2, 2025; 393(13)：1315-1326
IMAGES IN CLINICAL MEDICINE（临床医学图像）
10
Uremic Frost
尿毒症霜
M.A. Wani and Z.H. Shah
N Engl J Med; Oct 2, 2025; 393(13)：1327
11
Herpes Simplex Virus Esophagitis
单纯疱疹病毒食管炎
A.Agarwal and A. Agarwal
N Engl J Med; Oct 2, 2025; 393(13)：e21
CLINICAL PROBLEM-SOLVING（疑难杂症破解之道）
12
A Shifting Frame
视角转换
A.Terrett and Others
N Engl J Med; Oct 2, 2025; 393(13)：1328-1334
EDITORIALS（社论）
13
Data versus Dogma — Safety of Intravenous Rehydration in Severely Malnourished Children
数据与教条之争——严重营养不良儿童静脉补液的安全性
M.J. Peters
N Engl J Med; Oct 2, 2025; 393(13)：1336-1337
14
Studying Cancer Risks Associated with Diagnostic Procedures — Interpret Wisely
研究诊断程序相关的癌症风险——明智解读
L.M. Morton
N Engl J Med; Oct 2, 2025; 393(13)：1337-1339
CLINICAL DECISIONS（临床决策）
15
Allergy or Assumption of Allergy — When to Test for a Penicillin Allergy
过敏还是假定的过敏——何时进行青霉素过敏测试
H. Marwah , A. Ramsey , and E.M. Macy
N Engl J Med; Oct 2, 2025; 393(13)：1340-1342
CORRESPONDENCE（读者来信）
16
Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease
克莱斯罗维玛布用于有严重呼吸道合胞病毒疾病高风险的婴儿和儿童
N Engl J Med; Oct 2, 2025; 393(13)：1343-1345
17
Nerandomilast in Patients with Pulmonary Fibrosis
奈拉度米拉司特用于肺纤维化患者
N Engl J Med; Oct 2, 2025; 393(13)：1346-1347
18
Trastuzumab Deruxtecan in Gastric Cancer
德曲妥珠单抗用于胃癌
N Engl J Med; Oct 2, 2025; 393(13)：1347-1348
19
Tarlatamab in Small-Cell Lung Cancer
塔拉他玛布用于小细胞肺癌
N Engl J Med; Oct 2, 2025; 393(13)：1348-1349
20
Cyclophosphamide and Cyclosporin for GVHD Prevention
环磷酰胺和环孢素预防移植物抗宿主病
N Engl J Med; Oct 2, 2025; 393(13)：1349-1351
N Engl J Med[Jour] AND 393[volume] AND 14[issue]
新英格兰医学杂志 393卷14期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Occupational Health and Safety on the Chopping Block — What’s at Stake?
职业健康与安全岌岌可危——有何利害关系？
A.T. Gabrielson and C. Corwin
N Engl J Med; Oct 9, 2025; 393(14)：1353-1355
2
Emergency Medicaid at Risk — Preserving State Authority and Access to Care
紧急医疗补助岌岌可危——维护州政府权限与医疗保障可及性
J.A. Budhu and Others
N Engl J Med; Oct 9, 2025; 393(14)：1356-1358
3
Pharmaceutical Wholesalers — Under-the-Radar Middlemen?
药品批发商——鲜为人知的中间商？
H. Rooke-Ley and R.E. Sachs
N Engl J Med; Oct 9, 2025; 393(14)：1358-1360
4
“You Still Going to Be Doing This?”
“你还会坚持下去吗？”
E.J. Shapiro
N Engl J Med; Oct 9, 2025; 393(14)：1360-1361
ORIGINAL ARTICLES（论著）
5
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension
巴克斯德罗沙特（Baxdrostat）治疗未控制及难治性高血压的疗效与安全性
J.M. Flack and Others
N Engl J Med; Oct 9, 2025; 393(14)：1363-1374
6
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy
针对伴有多发性神经病的遗传性转甲状腺素蛋白淀粉样变性病的Nexiguran Ziclumeran基因编辑疗法
J.D. Gillmore and Others
N Engl J Med; Oct 9, 2025; 393(14)：1375-1386
7
Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases
靶向室内喷洒预防埃及伊蚊传播疾病的随机试验
N.E. Dean and Others
N Engl J Med; Oct 9, 2025; 393(14)：1387-1398
8
Permethrin-Treated Baby Wraps for the Prevention of Malaria
使用氯菊酯处理过的婴儿包裹物预防疟疾
R.M. Boyce and Others
N Engl J Med; Oct 9, 2025; 393(14)：1399-1408
REVIEW ARTICLE（综述）
9
Idiopathic Intracranial Hypertension
特发性颅内压增高
J.C. Horton
N Engl J Med; Oct 9, 2025; 393(14)：1409-1419
IMAGES IN CLINICAL MEDICINE（临床医学影像）
10
Butterfly Vertebra
蝴蝶椎
S. Ding and X. Pan
N Engl J Med; Oct 9, 2025; 393(14)：1420
11
Oral Verruciform Xanthomas
口腔疣状黄瘤
G. Anaya-Saavedra and M. Vázquez-Garduño
N Engl J Med; Oct 9, 2025; 393(14)：e22
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
12
Case 28-2025: A 36-Year-Old Man with Abdominal Pain, Fever, and Hypoxemia
2025年第28例病例：一例36岁男性，出现腹痛、发热伴低氧血症
G. Dhaliwal and Others
N Engl J Med; Oct 9, 2025; 393(14)：1421-1434
EDITORIAL（社论）
13
Aldosterone Synthase Inhibition for Hypertension
醛固酮合成酶抑制剂治疗高血压
T.J. Guzik and M. Tomaszewski
N Engl J Med; Oct 9, 2025; 393(14)：1436-1439
CORRESPONDENCE（读者来信）
14
Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel — Update
Exagamglogene Autotemcel中CRISPR-Cas9编码的特异性——更新
N Engl J Med; Oct 9, 2025; 393(14)：1440-1442
15
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes
每周固定剂量艾氟司他（Efsitora）胰岛素治疗2型糖尿病
N Engl J Med; Oct 9, 2025; 393(14)：1442-1444
16
Diphtheria Outbreak among Migrants in Europe
欧洲移民群体中的白喉疫情
N Engl J Med; Oct 9, 2025; 393(14)：1444-1445
17
Clearance of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling
通过恢复T细胞受体信号传导清除鳞状细胞癌
N Engl J Med; Oct 9, 2025; 393(14)：1446-1447
18
Case 17-2025: A Man with Respiratory Failure and Shock after Kidney Transplantation
2025年第17例病例：一例肾移植后出现呼吸衰竭和休克的患者
N Engl J Med; Oct 9, 2025; 393(14)：1447-1448
N Engl J Med[Jour] AND 393[volume] AND 15[issue]
新英格兰医学杂志 393卷15期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE(观点)
1
Reducing Tobacco Use Worldwide: The Contribution of Digital Treatment to Efforts to Reduce Global Tobacco Use
减少全球烟草使用:数字治疗对减少全球烟草使用的贡献
F. Naughton and A. Nadkarni
N Engl J Med; October16, 2025; 393(15):1449-1452
2
Advancing Surveillance of Health Care–Associated Infections — Targeting Hospital-Onset Sepsis
推进卫生保健相关感染的监测-针对医院发生的败血症
F. Manzoor , C. Rhee , and M. Klompas
N Engl J Med; October16, 2025; 393(15):1452-1454
3
The AI Frontier in Humanitarian Aid — Embracing Possibilities and Addressing Risks
人工智能在人道主义援助中的前沿——拥抱可能性与应对风险
M. Barry , J. Hansen , and G.L. Darmstadt
N Engl J Med; October16, 2025; 393(15):1454-1457
4
Proliferation of Prior Authorization in Traditional Medicare — None the WISeR?
传统医疗中预先授权的扩散——更明智了吗？
M. Liu , K.T. Kadakia , and R.K. Wadhera
N Engl J Med; October16, 2025; 393(15):1457-1459
5
On Bearing Witness
关于见证
S. Attar
N Engl J Med; October16, 2025; 393(15):1459-1461
6
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Alive and Kicking — NOS Episode 3.1
未作特别说明（NOS）——第三季：初级医疗的永恒危机：愈演愈烈 ——NOS第3季第1集
N Engl J Med; October16, 2025; 393(15):e24
ORIGINAL ARTICLES(论著)
7
Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer
宫颈癌中仅行前哨淋巴结活检或联合淋巴结清扫术
H. Tu and Others
N Engl J Med; October16, 2025; 393(15):1463-1474
8
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
Telitacicept治疗系统性红斑狼疮的3期临床试验
R.F. van Vollenhoven and Others
N Engl J Med; October16, 2025; 393(15):1475-1485
9
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency
基因治疗腺苷脱氨酶缺乏症的长期安全性和有效性
C. Booth and Others
N Engl J Med; October16, 2025; 393(15):1486-1497
10
Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality
马里婴儿大量使用阿奇霉素以降低死亡率
F.C. Haidara and Others
N Engl J Med; October16, 2025; 393(15):1498-1508
CLINICAL PRACTICE(临床实践)
11
Hair Loss in Women
女性脱发
E.A. Olsen
N Engl J Med; October16, 2025; 393(15):1509-1520
IMAGES IN CLINICAL MEDICINE(临床医学影像)
12
Pneumococcal Sepsis in a Patient with Asplenia and Hypogammaglobulinemia
脾缺失合并低丙种球蛋白血症患者发生肺炎球菌性败血症
S.J. Starke and I. Miller
N Engl J Med; October16, 2025; 393(15):1521
13
Stercoral Colitis
粪石性结肠炎
A. Bajer and E. Levine
N Engl J Med; October16, 2025; 393(15): e23
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL(马萨诸塞州总医院的病例记录)
14
Case 29-2025: A 43-Year-Old Woman with Depression, Suicidal Ideation, and Fever
病例29-2025：一例43岁女性，抑郁、自杀倾向伴发热
M.S. Abers and Others
N Engl J Med; October16, 2025; 393(15):1522-1531
EDITORIALS(社论)
15
Risk and Benefit
风险与收益
E.J. Rubin
N Engl J Med; October16, 2025; 393(15):1533-1534
16
Sentinel Lymphadenectomy for Early-Stage Cervical Cancer — the New Standard?
早期宫颈癌的前哨淋巴结切除术——新标准？
K. Bixel
N Engl J Med; October16, 2025; 393(15):1534-1536
MEDICINE AND SOCIETY(医学与社会)
17
The Primary Care Puzzle: Is a Long-Simmering Crisis Boiling Over? U.S. Primary Care Today
初级医疗之谜：长期酝酿的危机正在爆发？美国初级医疗现状
L. Rosenbaum
N Engl J Med; October16, 2025; 393(15):1537-1541
CORRESPONDENCE(通信)
18
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
体内CD19 CAR T细胞疗法治疗难治性系统性红斑狼疮
N Engl J Med; October16, 2025; 393(15):1542-1544
19
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
顽固性自身免疫性疾病患者的BCMA T细胞接合疗法
N Engl J Med; October16, 2025; 393(15):1544-1547
20
Competency-Based Medical Education at the Front Lines of Patient Care
以能力为本的一线患者护理医学教育
N Engl J Med; October16, 2025; 393(15):1548-1550
21
More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism
更多关于巴司他治疗原发性醛固酮增多症的2a期研究
N Engl J Med; October16, 2025; 393(15):1550-1552
N Engl J Med[Jour] AND 393[volume] AND 16[issue]
新英格兰医学杂志 393卷16期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Involving Palliative Care to Improve Outcomes in Sickle Cell Disease
纳入姑息治疗以改善镰状细胞病预后
E. Nwogu-Onyemkpa and Others
N Engl J Med; Oct 23, 2025; 393(16)：1553-1556
2
Thirty Years of Hydroxyurea for Sickle Cell Anemia — Scientific Progress, Global Health Gaps
羟基脲治疗镰状细胞贫血三十年——科学进展与全球健康差距
E. Costa and Others
N Engl J Med; Oct 23, 2025; 393(16)：1556-1559
3
Fetal Personhood and Reproductive Criminalization — Implications for Patients, Clinicians, and Public Health
胎儿人格与生殖犯罪化——对患者、临床医生和公共卫生的影响
T. Riley and A. Hassan
N Engl J Med; Oct 23, 2025; 393(16)：1559-1561
4
Living in the Present Tense
活在当下
J.A. Feinstein
N Engl J Med; Oct 23, 2025; 393(16)：1561-1563
5
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Can AI Solve Primary Care? — NOS Episode 3.2
未作他类说明——第三季：初级保健的永恒危机：人工智能能否解决初级保健问题？——未作他类说明第3.2集
N Engl J Med; Oct 23, 2025; 393(16)：e25
ORIGINAL ARTICLES（论著）
6
Hypertonic Saline or Carbocisteine in Bronchiectasis
高渗盐水或羧甲司坦治疗支气管扩张症
J.M. Bradley and Others
N Engl J Med; Oct 23, 2025; 393(16)：1565-1577
7
Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation
接受口服抗凝治疗的慢性冠状动脉综合征患者使用阿司匹林的情况
G. Lemesle and Others
N Engl J Med; Oct 23, 2025; 393(16)：1578-1588
8
Common Diseases in Clinical Cohorts — Not Always What They Seem
临床队列中的常见疾病——并不总是如表面所见
F. Rahimov and Others
N Engl J Med; Oct 23, 2025; 393(16)：1589-1598
9
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis
诊断后第一年内使用索塔生塞普（Sotatercept）治疗肺动脉高压
V.V. McLaughlin and Others
N Engl J Med; Oct 23, 2025; 393(16)：1599-1611
10
Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans
2024-2025年新冠疫苗与美国退伍军人新冠结局的关联
M. Cai , Y. Xie , and Z. Al-Aly
N Engl J Med; Oct 23, 2025; 393(16)：1612-1623
REVIEW ARTICLE（综述）
11
Medical Education: Educational Strategies to Prepare Trainees for Clinical Uncertainty
医学教育：为受训者应对临床不确定性做准备的教育策略
J.S. Ilgen and G. Dhaliwal
N Engl J Med; Oct 23, 2025; 393(16)：1624-1632
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Human East African Trypanosomiasis
人类东非锥虫病
L. Veletzky and S. Winkler
N Engl J Med; Oct 23, 2025; 393(16)：1633
13
Thoracic Ectopia Cordis
胸部心脏异位
Z. Duric and H. Gasparovic
N Engl J Med; Oct 23, 2025; 393(16)：e26
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
14
Case 30-2025: An 82-Year-Old Woman with Abdominal Distention, Edema, and Pleural Effusion
2025年30号病例：一名82岁女性，出现腹部膨隆、水肿和胸腔积液
Z. Kanjee and Others
N Engl J Med; Oct 23, 2025; 393(16)：1634-1644
EDITORIALS（社论）
15
Time to Reconsider Mucoactive Agents for Airway Clearance
是时候重新考虑用于气道廓清的黏液活性药物了
J. Hansen-Flaschen and G. Tino
N Engl J Med; Oct 23, 2025; 393(16)：1646-1647
16
A Rare-in-Common Paradigm for Precision Genomic Medicine
精准基因组医学中的“罕见共性”范式
P.N. Robinson
N Engl J Med; Oct 23, 2025; 393(16)：1648-1649
CORRESPONDENCE（读者来信）
17
Resurgence of Zoonotic Highly Pathogenic Avian Influenza A(H5N1) Virus in Cambodia
柬埔寨人畜共患高致病性禽流感A(H5N1)病毒卷土重来
N Engl J Med; Oct 23, 2025; 393(16)：1650-1652
18
Perioperative Durvalumab in Gastric Cancer
胃癌围手术期使用度伐利尤单抗
N Engl J Med; Oct 23, 2025; 393(16)：1652-1654
19
Tirzepatide vs. Semaglutide for Obesity Treatment
替西帕肽与司美格鲁肽治疗肥胖症的对比
N Engl J Med; Oct 23, 2025; 393(16)：1654-1656
N Engl J Med[Jour] AND 393[volume] AND 17[issue]
新英格兰医学杂志 393卷17期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Efforts toward Equity: Disparities in Kidney Disease and the Race-Neutral eGFR — Research and Action in NYC’s Public Hospital System
努力迈向公平：肾脏疾病中的差异与无种族差异的估算肾小球滤过率（eGFR）——纽约市公立医院系统的研究与行动
A. Bocour and Others
N Engl J Med; Oct 30, 2025; 393(17)：1657-1658
2
Efforts toward Equity: Automating WIC Screening and Enrollment in Pediatric Primary Care
努力迈向公平：儿科初级保健中妇女、婴儿和儿童（WIC）筛查与登记的自动化
L. Suarez and Others
N Engl J Med; Oct 30, 2025; 393(17)1659-1660
3
Efforts toward Equity: Listening and Responding to Community Voices — The Community Wellness HUB
努力迈向公平：倾听并回应社区声音——社区健康中心
L.S. Jemmott and Others
N Engl J Med; Oct 30, 2025; 393(17)：1660-1662
4
Flaws in the FDA’s New Priority Voucher Program
美国食品药品监督管理局（FDA）新优先审评券计划的缺陷
D. Carpenter , T.J. Hwang , and A.S. Kesselheim
N Engl J Med; Oct 30, 2025; 393(17)：1662-1664
5
Standing by Our Colleagues in Gaza — A Plea to the U.S. Medical Community
声援我们在加沙的同行——对美国医学界的呼吁
F. Sidhwa and Others
N Engl J Med; Oct 30, 2025; 393(17)：1664-1667
6
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Misunderstandings — NOS Episode 3.3
未明确说明——第三季：初级保健的长期危机：误解——未明确说明（NOS）第3.3集
N Engl J Med; Oct 30, 2025; 393(17)：e27
ORIGINAL ARTICLES（论著）
7
European Study of Prostate Cancer Screening — 23-Year Follow-up
欧洲前列腺癌筛查研究——23年随访结果
M.J. Roobol and Others
N Engl J Med; Oct 30, 2025; 393(17)：1669-1680
8
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
阿米万他单抗联合拉泽替尼治疗EGFR突变型晚期非小细胞肺癌的总生存期
J.C.-H. Yang and Others
N Engl J Med; Oct 30, 2025; 393(17)：1681-1693
9
A Randomized Trial of Physical Therapy for Meniscal Tear and Knee Pain
半月板撕裂和膝关节疼痛的物理治疗随机试验
J.N. Katz and Others
N Engl J Med; Oct 30, 2025; 393(17)：1694-1703
10
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine
甲型副伤寒沙门菌疫苗的安全性、有效性和免疫原性
N. McCann and Others
N Engl J Med; Oct 30, 2025; 393(17)：1704-1714
REVIEW ARTICLE（综述）
11
Noninvasive Assessment of Liver Fibrosis
肝脏纤维化的无创评估
L. Castera , M.E. Rinella , and E.A. Tsochatzis
N Engl J Med; Oct 30, 2025; 393(17)：1715-1729
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Herpes Simplex Virus Blepharitis
单纯疱疹病毒性睑缘炎
P. Ros-Arlanzón and M. Alcaraz-Graña
N Engl J Med; Oct 30, 2025; 393(17)：1730
13
Nasal Leech
鼻腔水蛭
W. Wu and J. Tan
N Engl J Med; Oct 30, 2025; 393(17)：e28
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
14
Case 31-2025: A 56-Year-Old Man with Left Lower Abdominal Pain and Anemia
病例31-2025：一例56岁男性，左侧下腹部疼痛伴贫血
B.E. Sands and Others
N Engl J Med; Oct 30, 2025; 393(17)：1731-1740
EDITORIALS（社论）
15
Early Detection of Prostate Cancer — Time to Fish or Cut Bait
前列腺癌的早期检测——是时候行动还是放弃
A. Vickers
N Engl J Med; Oct 30, 2025; 393(17)：1742-1743
16
EGFR-Mutated Lung Cancer — Letting the Butterfly Out of the Cocoon
EGFR突变型肺癌——破茧成蝶
A. Dimou and A. Mansfield
N Engl J Med; Oct 30, 2025; 393(17)：1743-1745
MEDICINE AND SOCIETY（医学与社论）
17
The Primary Care Puzzle: The Concierge Cure?
初级保健难题：私人医生服务是解决之道吗？
L. Rosenbaum
N Engl J Med; Oct 30, 2025; 393(17)：1746-1750
CORRESPONDENCE（读者来信）
18
Two-Year Outcomes after Transcatheter Arterialization of the Deep Veins
深静脉经导管动脉化两年后的疗效
N Engl J Med; Oct 30, 2025; 393(17)：1751-1753
19
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
非奈利酮联合恩格列净治疗慢性肾脏病和2型糖尿病
N Engl J Med; Oct 30, 2025; 393(17)：1753-1755
20
As-Needed Albuterol–Budesonide in Mild Asthma
按需使用沙丁胺醇-布地奈德治疗轻度哮喘
N Engl J Med; Oct 30, 2025; 393(17)：1755-1756
21
Donor Hearts for Transplantation after Circulatory Death
循环死亡后供体心脏的移植
N Engl J Med; Oct 30, 2025; 393(17)：1756-1760
N Engl J Med[Jour] AND 393[volume] AND 18[issue]
新英格兰医学杂志 393卷18期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: The Antitrust Antidote to Hospital and Nursing Home Corporatization — Promises and Pitfalls
美国医疗保健的企业化：用反垄断法应对医院和养老院企业化——承诺与陷阱
Y. Singh
N Engl J Med; Nov 6, 2025; 393(18)：1761-1764
2
Adverse Health Effects of Energy-Related Provisions in the “One Big Beautiful Bill”
“宏伟美丽法案”中能源相关条款对健康的不利影响
R.L. Glicksman
N Engl J Med; Nov 6, 2025; 393(18)：1764-1766
3
Medicaid Cuts and U.S. Children’s Health — Fixing a Broken System
医疗补助削减与美国儿童健康——修复破碎的体系
E.E. McGinty , A. Bitton , and S.R. Permar
N Engl J Med; Nov 6, 2025; 393(18)：1766-1769
4
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: If You Break It, 未作其他说明——第三季：初级保健的永恒危机：若你将其破坏
They Won’t Come — NOS Episode 3.4
N Engl J Med; Nov 6, 2025; 393(18)：e29
5
Perspective Roundtable: Pursuing Health Equity in the United States
观点圆桌会议：在美国追求健康公平
C.W. Cené and Others
N Engl J Med; Nov 6, 2025; 393(18)：e30
ORIGINAL ARTICLES（论著）
6
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer
乳腺癌术后胸壁放疗的十年生存率
I.H. Kunkler and Others
N Engl J Med; Nov 6, 2025; 393(18)：1771-1783
7
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
口服伊可曲金拉治疗成人和青少年斑块状银屑病
R. Bissonnette and Others
N Engl J Med; Nov 6, 2025; 393(18)：1784-1795
8
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
奥福格列隆：一种用于肥胖治疗的口服小分子GLP-1受体激动剂
S. Wharton and Others
N Engl J Med; Nov 6, 2025; 393(18)：1796-1806
9
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate
一种rVSV拉沙热候选疫苗的安全性和免疫原性
E. Malkin and Others
N Engl J Med; Nov 6, 2025; 393(18)：1807-1818
10
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer
塞瓦伯替尼治疗晚期HER2突变型非小细胞肺癌
X. Le and Others
N Engl J Med; Nov 6, 2025; 393(18)：1819-1832
CLINICAL PRACTICE（临床实践）
11
Opioid Deprescribing in Patients with Noncancer Pain
非癌性疼痛患者的阿片类药物减量
C.-W.C. Lin and A.V. Langford
N Engl J Med; Nov 6, 2025; 393(18)：1833-1842
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Patent Persistent Omphalomesenteric Duct
持续性脐肠管未闭
P.-L. Verot and P.-Y. Rabattu
N Engl J Med; Nov 6, 2025; 393(18)：1843
13
Goiter, Bounding Pulses, and Thyroid Bruit in Thyroid Storm
甲状腺危象中的甲状腺肿、洪脉和甲状腺杂音
T. Yagi and T. Kawasaki
N Engl J Med; Nov 6, 2025; 393(18)：e31
CLINICAL PROBLEM-SOLVING（临床问题解决）
14
Spiraling into a Distant Past
陷入遥远的过去
J. Van den Eynde and Others
N Engl J Med; Nov 6, 2025; 393(18)：1844-1850
EDITORIALS（社论）
15
Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer
乳腺癌乳房切除术后省略胸壁放疗
J. de Boniface
N Engl J Med; Nov 6, 2025; 393(18)：1852-1853
16
Oral Psoriasis Therapy — For Whom and at What Cost and Risk?
口服银屑病疗法——适用于哪些患者，成本和风险如何？
R.S. Stern
N Engl J Med; Nov 6, 2025; 393(18)：1854-1855
CLINICAL DECISIONS（临床决策）
17
Carotid-Artery Stenting or Carotid Endarterectomy for Symptomatic Carotid-Artery Stenosis?
症状性颈动脉狭窄：颈动脉支架置入术还是颈动脉内膜切除术？
S. Gorey , G.J. de Borst , and T.N. Nguyen
N Engl J Med; Nov 6, 2025; 393(18)：1856-1858
CORRESPONDENCE（读者来信）
18
Cold Perfusion vs. Static Cold Storage of Deceased-Donor Kidneys — at 10 Years
已故供体肾脏的冷灌注与静态冷保存——10年对比
N Engl J Med; Nov 6, 2025; 393(18)：1859-1861
19
Vepdegestrant in Advanced Breast Cancer
维培吉司他治疗晚期乳腺癌
N Engl J Med; Nov 6, 2025; 393(18)：1861-1862
20
Testosterone for Middle-Aged and Older Men with Hypogonadism
睾酮治疗中老年男性性腺功能减退症
N Engl J Med; Nov 6, 2025; 393(18)：1863-1864
N Engl J Med[Jour] AND 393[volume] AND 19[issue]
新英格兰医学杂志 393卷19期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Erosion of Harm Reduction
损害减少策略的削弱
J.A. Barocas
N Engl J Med; Nov 13, 2025; 393(19)：1865-1867
2
Religious Liberty as a Shield for Public Health — The Case of Overdose-Prevention Centers
宗教自由作为公共卫生的护盾——过量预防中心案例
B.A. Barsky , A. Caplan-Bricker , and C. Robertson
N Engl J Med; Nov 13, 2025; 393(19)：1867-1869
3
Truly Prioritizing Child Health — The Missed Opportunities of the MAHA Commission
真正将儿童健康置于首位——MAHA委员会错失的机遇
J.M. Perrin and T.L. Cheng
N Engl J Med; Nov 13, 2025; 393(19)：1869-1872
4
What Is Hospice?
什么是临终关怀？
T.D. Brender
N Engl J Med; Nov 13, 2025; 393(19)：1872-1873
5
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Undervalued — NOS Episode 3.5
未作特别说明——第三季：初级保健的永恒危机：价值被低估——NOS 第 3.5 集
N Engl J Med; Nov 13, 2025; 393(19)：e32
ORIGINAL ARTICLES（论著）
6
Deferring Arterial Catheterization in Critically Ill Patients with Shock
对休克危重患者推迟动脉导管置入术
G. Muller and Others
N Engl J Med; Nov 13, 2025; 393(19)：1875-1888
7
Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction
无射血分数降低的心肌梗死后使用β受体阻滞剂
B. Ibanez and Others
N Engl J Med; Nov 13, 2025; 393(19)：1889-1900
8
Beta-Blockers after Myocardial Infarction in Patients without Heart Failure
无心力衰竭的心肌梗死后患者使用β受体阻滞剂
J. Munkhaugen and Others
N Engl J Med; Nov 13, 2025; 393(19)：1901-1911
9
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
Sacituzumab Govitecan 用于未经治疗的晚期三阴性乳腺癌
J. Cortés and Others
N Engl J Med; Nov 13, 2025; 393(19)：1912-1925
REVIEW ARTICLE（综述）
10
Acromegaly
肢端肥大症
A. Giustina and A. Colao
N Engl J Med; Nov 13, 2025; 393(19)：1926-1939
IMAGES IN CLINICAL MEDICINE（临床医学影像）
11
Erythema Infectiosum
传染性红斑
J. Martinez-Coronado and R. Salazar
N Engl J Med; Nov 13, 2025; 393(19)：1940
12
Forehead Venous Pulsations in Severe Tricuspid Regurgitation
严重三尖瓣反流患者的额部静脉搏动
E.F. Aleong and Y.S. Chatzizisis
N Engl J Med; Nov 13, 2025; 393(19)：e33
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
13
Case 32-2025: A 79-Year-Old Man with Dyspnea, Edema, and Pacemaker-Lead Displacement
病例 32-2025：一例79 岁男性，出现呼吸困难、水肿和起搏器导线移位
J. Liu and Others
N Engl J Med; Nov 13, 2025; 393(19)：1941-1951
EDITORIAL（社论）
14
A Less Invasive Approach to Intensive Care
重症监护的侵入性较小的治疗方法
H.B. Gershengorn
N Engl J Med; Nov 13, 2025; 393(19)：1953-1954
MEDICINE AND SOCIETY（医学与社会）
15
The Primary Care Puzzle: PCPs, APPs, and the Everything Bagel Problem — Choosing Not to Choose
初级保健难题：初级保健医生、高级实践护士与“全能包”问题——选择不选择
L. Rosenbaum
N Engl J Med; Nov 13, 2025; 393(19)：1955-1959
CORRESPONDENCE（读者来信）
16
A Mammarenavirus Close to Lassa Virus in a Patient with Meningoencephalitis
一名脑膜脑炎患者体内发现与拉沙病毒接近的哺乳动物雷斯顿病毒
N Engl J Med; Nov 13, 2025; 393(19)：1960-1962
17
Acute Normovolemic Hemodilution in Cardiac Surgery
心脏手术中的急性等容性血液稀释
N Engl J Med; Nov 13, 2025; 393(19)：1963-1964
18
Adjuvant Cemiplimab in Cutaneous Squamous-Cell Carcinoma
辅助西米普利单抗治疗皮肤鳞状细胞癌
N Engl J Med; Nov 13, 2025; 393(19)：1964-1965
19
Educational Strategies for Clinical Supervision of Artificial Intelligence Use
人工智能使用临床监督的教育策略
N Engl J Med; Nov 13, 2025; 393(19)：1965-1968
N Engl J Med[Jour] AND 393[volume] AND 20[issue]
新英格兰医学杂志 393卷20期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Tobacco Use Reduction: Integration of Tobacco-Cessation Interventions into Tuberculosis and HIV Care
减少烟草使用：将戒烟干预措施纳入结核病和艾滋病护理
J. Shuter , S. Goel , and S.S. Himelhoch
N Engl J Med; Nov 20, 2025; 393(20)：1969-1972
2
Regulating Corporate Control in Health Care — Oregon’s Attempt to Revive the CPOM Doctrine
规范医疗保健中的企业控制——俄勒冈州尝试重振“专业执业组织”原则
J.M. Zhu and H. Rooke-Ley
N Engl J Med; Nov 20, 2025; 393(20)：1972-1974
3
Pistachio Ice Cream
开心果冰淇淋
B.B. Kamdar
N Engl J Med; Nov 20, 2025; 393(20)：1975-1977
ORIGINAL ARTICLES（论著）
4
Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias
提高高危室性心律失常患者的血钾水平
C. Jøns and Others
N Engl J Med; Nov 20, 2025; 393(20)：1979-1989
5
Reduction of Antihypertensive Treatment in Nursing Home Residents
减少养老院居民的抗高血压治疗
A. Benetos and Others
N Engl J Med; Nov 20, 2025; 393(20)：1990-2000
6
Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine
改良信使核糖核酸（mRNA）流感疫苗的有效性、免疫原性和安全性
D. Fitz-Patrick and Others
N Engl J Med; Nov 20, 2025; 393(20)：2001-2011
7
Belzutifan for Advanced Pheochromocytoma or Paraganglioma
Belzutifan治疗晚期嗜铬细胞瘤或副神经节瘤
B. Jimenez and Others
N Engl J Med; Nov 20, 2025; 393(20)：2012-2022
REVIEW ARTICLE（综述）
8
Long QT Syndrome
长QT综合征
P.J. Schwartz and L. Crotti
N Engl J Med; Nov 20, 2025; 393(20)：2023-2034
IMAGES IN CLINICAL MEDICINE（临床医学影像）
9
Cutaneous Metastases from Breast Carcinoma
乳腺癌的皮肤转移
Y.-H. Hsu and H.-J. Wang
N Engl J Med; Nov 20, 2025; 393(20)：2035
10
Ortner’s Syndrome in Pulmonary Hypertension
肺动脉高压伴发的奥特纳综合征
R. Plácido and B. Baptista
N Engl J Med; Nov 20, 2025; 393(20)：e35
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
11
Case 33-2025: A 27-Year-Old Man with Abnormal Behaviors, Confusion, and Seizure
病例33-2025：一例27岁男性，出现行为异常、意识模糊和癫痫发作
N.V. Quijije and Others
N Engl J Med; Nov 20, 2025; 393(20)：2036-2045
EDITORIALS（社论）
12
Targeting Potassium for Prevention of Ventricular Arrhythmias
以钾为靶点预防室性心律失常
N.A. Chatterjee
N Engl J Med; Nov 20, 2025; 393(20)：2047-2048
13
An Early Look at mRNA Vaccines to Prevent Influenza
预防流感的信使核糖核酸（mRNA）疫苗的早期审视
H.M. El Sahly and R.L. Atmar
N Engl J Med; Nov 20, 2025; 393(20)：2048-2050
CLINICAL DECISIONS（临床决策）
14
To Treat or Not to Treat? Watchful Waiting or Oral Antihypertensives for Asymptomatic Inpatient Hypertension
治疗还是不治疗？无症状住院高血压患者的观察等待或口服抗高血压药物选择
S. Gorey , M. Rothberg , and T.I.-H. Chang
N Engl J Med; Nov 20, 2025; 393(20)：2051-2053
CLINICAL IMPLICATIONS OF BASIC RESEARCH（基础研究的临床意义）
15
A New Stage for Seasoned Actors — Food Anaphylaxis and the Cysteinyl Leukotrienes
资深“演员”的新舞台——食物过敏性休克与半胱氨酰白三烯
J.A. Boyce
N Engl J Med; Nov 20, 2025; 393(20)：2054-2057
MEDICINE AND SOCIETY（医学与社会）
16
The Primary Care Puzzle: Why Have We Chosen Not to Fix Primary Care? The Vicious Cycle of Medical Hierarchy
初级保健难题：我们为何选择不修复初级保健？医疗等级制度的恶性循环
L. Rosenbaum
N Engl J Med; Nov 20, 2025; 393(20)：2058-2062
CORRESPONDENCE（读者来信）
17Toward Same-Day Genome Sequencing in the Critical Care Setting
在重症监护环境中实现当日基因组测序
N Engl J Med; Nov 20, 2025; 393(20)：2063-2065
18
Cagrilintide–Semaglutide in Adults with Overweight or Obesity
Cagrilintide-Semaglutide治疗超重或肥胖成人
N Engl J Med; Nov 20, 2025; 393(20)：2065-2068
19
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
新辅助纳武利尤单抗联合化疗治疗肺癌
N Engl J Med; Nov 20, 2025; 393(20)：2068-2070
20
Pathogenesis of Heparin-Induced Thrombocytopenia
肝素诱导的血小板减少症的发病机制
N Engl J Med; Nov 20, 2025; 393(20)：2070-2071
N Engl J Med[Jour] AND 393[volume] AND 21[issue]
新英格兰医学杂志 393卷21期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
Untangling the Risks of Antidepressants in Pregnancy
理清孕期服用抗抑郁药的风险
K.F. Huybrechts , S. Hernández-Díaz , and B.T. Bateman
N Engl J Med; Nov 27, 2025; 393(21)：2073-2075
2
Restoring Confidence in Public Health
重拾对公共卫生的信心
P. Marks
N Engl J Med; Nov 27, 2025; 393(21)：2075-2077
3
Venture Capital Investments by U.S. Academic Medical Centers
美国学术医疗中心的风险投资
N. Uppal and Z. Song
N Engl J Med; Nov 27, 2025; 393(21)：2077-2080
4
A Wrinkled White Coat
皱巴巴的白大褂
M.A. Pacult
N Engl J Med; Nov 27, 2025; 393(21)：2080-2081
5
Not Otherwise Specified — Season 3: The Forever Crisis of Primary Care: Doctor with a Capital D — NOS Episode 3.6
非特别说明——第3季：初级保健的永恒危机：有着大写D的医生——非特别说明第3.6集
N Engl J Med; Nov 27, 2025; 393(21)：e34
ORIGINAL ARTICLES（论著）
6
Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction
低风险急性心肌梗死患者经皮冠状动脉介入治疗（PCI）后早期停用阿司匹林
G. Tarantini and Others
N Engl J Med; Nov 27, 2025; 393(21)：2083-2094
7
Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes
急性冠状动脉综合征患者经皮冠状动脉介入治疗后早期停用阿司匹林
P.O. Guimarães and Others
N Engl J Med; Nov 27, 2025; 393(21)：2095-2106
8
Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model
在可控人体感染模型中，每日服用莫努那韦作为登革热预防措施
A.P. Durbin and Others
N Engl J Med; Nov 27, 2025; 393(21)：2107-2118
9
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3
针对ANGPTL3的CRISPR-Cas9基因编辑1期试验
L.J. Laffin and Others
N Engl J Med; Nov 27, 2025; 393(21)：2119-2130
10
Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia
恩加塞替尼与安慰剂治疗遗传性出血性毛细血管扩张症出血的对比研究
H. Al-Samkari and Others
N Engl J Med; Nov 27, 2025; 393(21)：2131-2141
REVIEW ARTICLE（综述）
11
Medical Education: Strategies to Reinvigorate the Bedside Clinical Encounter
医学教育：重振床边临床诊疗的策略
B.T. Garibaldi and S.W. Russell
N Engl J Med; Nov 27, 2025; 393(21)：2142-2150
IMAGES IN CLINICAL MEDICINE（临床医学影像）
12
Spironolactone-Induced Gynecomastia
螺内酯引起的男性乳房发育症
A.I. Celik and T. Bezgin
N Engl J Med; Nov 27, 2025; 393(21)：2151
13
Subcutaneous Dirofilariasis
皮下丝虫病
R. Moroti Constantinescu and G.A. Dumitru
N Engl J Med; Nov 27, 2025; 393(21)：e37
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL（马萨诸塞州总医院病例记录）
14
Case 34-2025: A 57-Year-Old Woman with Visual Disturbances and Right-Arm Shaking
2025年第34例病例：一例57岁女性，出现视觉障碍与右臂震颤
N. Wang and Others
N Engl J Med; Nov 27, 2025; 393(21)：2152-2162
EDITORIALS（社论）
15
Discontinuation of Aspirin in Acute Coronary Syndromes Treated with Coronary-Artery Stents
冠状动脉支架置入术治疗急性冠状动脉综合征后停用阿司匹林
J.A. Leopold
N Engl J Med; Nov 27, 2025; 393(21)：2164-2166
16
Toward a Dengue Pill
迈向登革热药物
X. Xie
N Engl J Med; Nov 27, 2025; 393(21)：2166-2167
CORRESPONDENCE（读者来信）
17
Adrenal Aldosterone Synthase Expression Imaging in Primary Aldosteronism
原发性醛固酮增多症肾上腺醛固酮合成酶表达成像
N Engl J Med; Nov 27, 2025; 393(21)：2168-2170
18
Osilodrostat for Bilateral Adrenal Hypercortisolism in Primary Aldosteronism
奥西洛司他治疗原发性醛固酮增多症伴双侧肾上腺皮质醇增多症
N Engl J Med; Nov 27, 2025; 393(21)：2170-2172
19
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
低剂量阿司匹林治疗PI3K突变的局部结直肠癌
N Engl J Med; Nov 27, 2025; 393(21)：2173
20
Cardiac Rehabilitation for Older Patients
老年患者的心脏康复
N Engl J Med; Nov 27, 2025; 393(21)：2173-2175
21
Medications for Opioid Use Disorder in County Jails — Outcomes after Release
县监狱中阿片类药物使用障碍患者的药物治疗——释放后的结果
N Engl J Med; Nov 27, 2025; 393(21)：2175-2176
N Engl J Med[Jour] AND 393[volume] AND 22[issue]
新英格兰医学杂志 393卷22期
https://www.nejm.org/toc/nejm/medical-journal?query=main_nav_lg
PERSPECTIVE（观点）
1
The Corporatization of U.S. Health Care: Has Corporatization Met Its Match? The Challenge of Making Money by Keeping People Healthy
美国医疗保健的企业化：企业化是否遇到了对手？通过保持人们健康来盈利的挑战
D.M. Cutler and R.S. Huckman
N Engl J Med; Dec 4, 2025; 393(22)：2177-2180
2
The New U.S. Global Health Strategy — A Reset of America’s Health Cooperation
美国新的全球卫生战略——美国卫生合作的重置
J. Ratevosian and Others
N Engl J Med; Dec 4, 2025; 393(22)：2180-2182
3
From Bandwidth to Bedside — Bringing AI-Enabled Care to Rural America
从带宽到病床边——将人工智能赋能的医疗服务带到美国农村地区
A.E. Volandes , A.D. Davis , and N.E. Goldstein
N Engl J Med; Dec 4, 2025; 393(22)：2182-2185
ORIGINAL ARTICLES（论著）
4
A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia
社区获得性肺炎糖皮质激素的实用试验
R.K. Lucinde and Others
N Engl J Med; Dec 4, 2025; 393(22)：2187-2197
5
A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus
特发性正常压力脑积水分流术的随机试验
M.G. Luciano and Others
N Engl J Med; Dec 4, 2025; 393(22)：2198-2209
6
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
Pegcetacoplan治疗C3肾小球病和免疫复合物膜增生性肾小球肾炎的试验
F. Fakhouri and Others
N Engl J Med; Dec 4, 2025; 393(22)：2210-2220
SPECIAL ARTICLE（专题）
7
Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026
2025 - 2026年新冠肺炎、呼吸道合胞病毒和流感疫苗的最新证据
J. Scott and Others
N Engl J Med; Dec 4, 2025; 393(22)：2221-2242
REVIEW ARTICLE（综述）
8
Idiopathic Normal-Pressure Hydrocephalus
特发性正常压力脑积水
M.D. Johnson and M.A. Williams
N Engl J Med; Dec 4, 2025; 393(22)：2243-2253
IMAGES IN CLINICAL MEDICINE（临床医学影像）
9
Complete Heart Block Detected by Consumer-Facing Digital Health Technologies
消费级数字健康技术检测到的完全性房室传导阻滞
J.E. Ip
N Engl J Med; Dec 4, 2025; 393(22)：2254
10
Empyema Necessitans
脓胸穿孔
A.Ayoola and K. Zejnullahu
N Engl J Med; Dec 4, 2025; 393(22)：e38
CLINICAL PROBLEM-SOLVING（临床疑难问答）
11
Clouded by Smoke
烟雾笼罩
D.R. Soled and Others
N Engl J Med; Dec 4, 2025; 393(22)：2255-2261
EDITORIALS（社论）
12
Glucocorticoids for Pneumonia in Africa — Old Therapy, New Context
非洲肺炎的糖皮质激素治疗——旧疗法，新背景
A.Kwizera and M.W. Dünser
N Engl J Med; Dec 4, 2025; 393(22)：2263-2264
13
Small Steps, Big Ventricles: Idiopathic Normal-Pressure Hydrocephalus
小步伐，大心室：特发性正常压力脑积水
A.H. Ropper
N Engl J Med; Dec 4, 2025; 393(22)：2264-2266
14
Pegcetacoplan for Treatment of C3 Glomerulopathy and Immune-Complex MPGN
Pegcetacoplan治疗C3肾小球病和免疫复合物膜增生性肾小球肾炎
L. Zand and F.C. Fervenza
N Engl J Med; Dec 4, 2025; 393(22)：2266-2267
CLINICAL DECISIONS（临床决策）
15
Simplify or Stratify? The Debate over Medical School Grading Systems
简化还是分层？医学院评分系统的争论
H. Marwah and Others
N Engl J Med; Dec 4, 2025; 393(22)：2268-2270
CORRESPONDENCE（读者来信）
16
Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk
感染奶牛的牛奶和加标牛奶中禽流感A(H5N1)病毒的稳定性
N Engl J Med; Dec 4, 2025; 393(22)：2271-2273
17
Once-Monthly Maridebart Cafraglutide in Obesity — A Phase 2 Trial
每月一次的Maridebart Cafraglutide治疗肥胖症——一项2期试验
N Engl J Med; Dec 4, 2025; 393(22)：2274-2275
18
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Orforglipron（一种口服胰高糖素样肽-1受体激动剂）治疗早期2型糖尿病
N Engl J Med; Dec 4, 2025; 393(22)：2276-2279
19
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
基于可测量残留病灶指导的慢性淋巴细胞白血病治疗
N Engl J Med; Dec 4, 2025; 393(22)：2279-2280
临床结果临床2期
2025-11-28
·知乎专栏
近日，美国食品药品监督管理局（FDA）批准了一批创新药物和新适应症疗法，涵盖肾脏疾病、基因疗法、骨质疏松、癌症、罕见遗传病等多个领域，为临床治疗提供了更多选择。以下为部分重点药物及其临床用途：一、肾脏疾病治疗新选择：Voyxact公司：大冢制药（Otsuka Pharmaceutical Co., Ltd）批准日期：2025年11月25日适应症：原发性免疫球蛋白A肾病（IgAN）药物机制：Voyxact（sibeprenlimab-szsi）为APRIL阻断剂，可显著减少蛋白尿，降低疾病进展风险。可由患者或护理人员每四周在家庭条件下注射，方便长期管理。临床研究显示，Voyxact在九个月的治疗中能够降低成人IgAN患者的尿蛋白水平，为慢性肾病患者提供了新的治疗方案。FDA对其授予加速批准，以应对高风险患者的迫切需求。二、基因疗法：Itvisma公司：诺华制药（Novartis Pharmaceuticals Corporation）批准日期：2025年11月24日适应症：脊髓性肌萎缩症（SMA）药物机制：Itvisma（onasemnogene abeparvovec-brve）为腺相关病毒（AAV）载体基因疗法，可替代SMN1基因，用于两岁及以上患者。Itvisma为首个面向更广泛SMA患者群体的基因替代疗法，临床数据显示可改善运动功能和疾病进程，为患者提供重要治疗选择。三、骨骼相关治疗新药：Osvyrti 与 Jubereq公司：Accord BioPharma, Inc.批准日期：2025年11月20日适应症：骨质疏松、骨肿瘤相关骨病变药物机制：两者均为RANKL抑制剂生物类似药，分别对应Prolia和Xgeva，用于骨质疏松以及多发性骨髓瘤、骨转移肿瘤患者的骨相关事件预防。癌症治疗新进展Hyrnuo（sevabertinib）：Bayer研发的HER2突变非小细胞肺癌可逆性酪氨酸激酶抑制剂，2025年11月19日获FDA加速批准。Komzifti（ziftomenib）：Kura Oncology与Kyowa Kirin联合研发，获批用于复发或难治NPM1突变急性髓性白血病。Poherdy（pertuzumab-dpzb）：上海恒立生物与Organon联合研发HER2阳性乳腺癌可互换生物类似药。四、罕见疾病与遗传病Redemplo（plozasiran）：针对家族性乳糜微粒血症的siRNA药物，可辅助饮食降低成人甘油三酯水平。Kygevvi（doxecitine + doxribtimine）：用于胸苷激酶2缺乏症的组合核苷药物，可用于成人及12岁前发病的儿童。五、其他重要批准药物Lynkuet：用于缓解更年期中度至重度潮热症状。Javadin：可口服的高血压药物制剂。Contepo：用于复杂性尿路感染的注射剂。Epioxa：角膜交联治疗圆锥角膜。Ferabright：脑部MRI用铁对比剂。Eydenzelt：湿性黄斑变性及糖尿病相关视网膜疾病的VEGF抑制剂生物类似药。此次FDA批准的多款药物覆盖临床急需领域，包括慢性肾病、神经退行性疾病、骨病、癌症及罕见遗传病，为医生和患者提供了更多精准治疗选择，也标志着药物研发领域在创新和生物类似药应用上的持续突破。结语随着临床治疗手段不断更新，FDA批准的药物不仅拓展了患者的治疗选择，也为疾病管理提供了更多可能性。医疗机构、医生和患者可根据最新临床指南，结合药物特点，优化治疗方案。Eltromin 25mg/50mg Eltrombopag 艾曲波帕Enatinib 4mg/10mg Lenvatinib 乐伐替尼Lynparib 150mg Olaparib 奥拉帕利Coltinib 15mg Upadacitini 乌帕达替尼Alvonib 80mg Osimertinib 奥希替尼法玛希Pharmacil 科诺Techno孟加拉制药官网：瑞德安 Radiant
基因疗法上市批准siRNA加速审批
2025-11-28
·康知伴
近日，美国食品药品监督管理局（FDA）批准了一批创新药物和新适应症疗法，涵盖肾脏疾病、基因疗法、骨质疏松、癌症、罕见遗传病等多个领域，为临床治疗提供了更多选择。以下为部分重点药物及其临床用途：
Q
一、肾脏疾病治疗新选择：Voyxact
公司：大冢制药（Otsuka Pharmaceutical Co., Ltd）
批准日期：2025年11月25日
适应症：原发性免疫球蛋白A肾病（IgAN）
药物机制：Voyxact（sibeprenlimab-szsi）为APRIL阻断剂，可显著减少蛋白尿，降低疾病进展风险。可由患者或护理人员每四周在家庭条件下注射，方便长期管理。
临床研究显示，Voyxact在九个月的治疗中能够降低成人IgAN患者的尿蛋白水平，为慢性肾病患者提供了新的治疗方案。FDA对其授予加速批准，以应对高风险患者的迫切需求。
Q
二、基因疗法：Itvisma
公司：诺华制药（Novartis Pharmaceuticals Corporation）
批准日期：2025年11月24日
适应症：脊髓性肌萎缩症（SMA）
药物机制：Itvisma（onasemnogene abeparvovec-brve）为腺相关病毒（AAV）载体基因疗法，可替代SMN1基因，用于两岁及以上患者。
Itvisma为首个面向更广泛SMA患者群体的基因替代疗法，临床数据显示可改善运动功能和疾病进程，为患者提供重要治疗选择。
Q
三、骨骼相关治疗新药：Osvyrti 与 Jubereq
公司：Accord BioPharma, Inc.
批准日期：2025年11月20日
适应症：骨质疏松、骨肿瘤相关骨病变
药物机制：两者均为RANKL抑制剂生物类似药，分别对应Prolia和Xgeva，用于骨质疏松以及多发性骨髓瘤、骨转移肿瘤患者的骨相关事件预防。
癌症治疗新进展
Hyrnuo（sevabertinib）：Bayer研发的HER2突变非小细胞肺癌可逆性酪氨酸激酶抑制剂，2025年11月19日获FDA加速批准。
Komzifti（ziftomenib）：Kura Oncology与Kyowa Kirin联合研发，获批用于复发或难治NPM1突变急性髓性白血病。
Poherdy（pertuzumab-dpzb）：上海恒立生物与Organon联合研发HER2阳性乳腺癌可互换生物类似药。
Q
四、罕见疾病与遗传病
Redemplo（plozasiran）：针对家族性乳糜微粒血症的siRNA药物，可辅助饮食降低成人甘油三酯水平。
Kygevvi（doxecitine + doxribtimine）：用于胸苷激酶2缺乏症的组合核苷药物，可用于成人及12岁前发病的儿童。
Q
五、其他重要批准药物
Lynkuet：用于缓解更年期中度至重度潮热症状。
Javadin：可口服的高血压药物制剂。
Contepo：用于复杂性尿路感染的注射剂。
Epioxa：角膜交联治疗圆锥角膜。
Ferabright：脑部MRI用铁对比剂。
Eydenzelt：湿性黄斑变性及糖尿病相关视网膜疾病的VEGF抑制剂生物类似药。
此次FDA批准的多款药物覆盖临床急需领域，包括慢性肾病、神经退行性疾病、骨病、癌症及罕见遗传病，为医生和患者提供了更多精准治疗选择，也标志着药物研发领域在创新和生物类似药应用上的持续突破。
Q
结语
随着临床治疗手段不断更新，FDA批准的药物不仅拓展了患者的治疗选择，也为疾病管理提供了更多可能性。医疗机构、医生和患者可根据最新临床指南，结合药物特点，优化治疗方案。
Eltromin 25mg/50mg Eltrombopag 艾曲波帕
Enatinib 4mg/10mg Lenvatinib 乐伐替尼
Lynparib 150mg Olaparib 奥拉帕利
Coltinib 15mg Upadacitini 乌帕达替尼
Alvonib 80mg Osimertinib 奥希替尼
法玛希Pharmacil 科诺Techno
孟加拉制药官网：www.radiantpharmacil.com
瑞德安 Radiant
上市批准基因疗法siRNA
100 项与 依林扎奈坦 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 依林扎奈坦 | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血管舒缩症 | 美国 | 2025-10-24 | |
| 潮热 | 加拿大 | 2025-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 入睡和睡眠障碍 | 临床2期 | 美国 | 2023-11-08 | |
| 入睡和睡眠障碍 | 临床2期 | 奥地利 | 2023-11-08 | |
| 入睡和睡眠障碍 | 临床2期 | 比利时 | 2023-11-08 | |
| 入睡和睡眠障碍 | 临床2期 | 捷克 | 2023-11-08 | |
| 入睡和睡眠障碍 | 临床2期 | 德国 | 2023-11-08 | |
| 入睡和睡眠障碍 | 临床2期 | 波兰 | 2023-11-08 | |
| 入睡和睡眠障碍 | 临床2期 | 西班牙 | 2023-11-08 | |
| 睡眠异常 | 临床2期 | 美国 | 2018-11-20 | |
| 睡眠异常 | 临床2期 | 美国 | 2018-11-20 | |
| 睡眠异常 | 临床2期 | 加拿大 | 2018-11-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 628 | (Elinzanetant (BAY3427080)) | 鏇觸膚範衊廠選遞鏇鑰(餘蓋齋齋鏇願醖齋觸鹹) = 鏇鹹鏇淵網夢繭膚襯醖 鬱衊築築繭糧醖鑰觸襯 (鹽淵糧獵夢製衊願觸鹹, 7.15) 更多 | - | 2025-12-01 | ||
Placebo (Placebo) | 鏇觸膚範衊廠選遞鏇鑰(餘蓋齋齋鏇願醖齋觸鹹) = 齋觸廠糧襯醖淵壓簾糧 鬱衊築築繭糧醖鑰觸襯 (鹽淵糧獵夢製衊願觸鹹, 6.15) 更多 | ||||||
临床3期 | 628 | Elinzanetant 120 mg | 構範廠淵餘獵淵遞餘艱(鹹鏇夢夢壓窪蓋獵齋顧) = numerical advantages for elinzanetant vs placebo for improving VMS frequency and severity 觸齋膚網齋鹹鹹觸鑰鏇 (積鬱鹽積淵艱築糧簾夢 ) 更多 | 积极 | 2025-11-01 | ||
Placebo | |||||||
临床3期 | 474 | 獵壓窪選鏇選齋鏇餘遞(廠鏇鹹遞製積蓋鬱積積) = 衊簾衊構遞範鹽網廠淵 築構齋壓餘製鑰繭觸襯 (繭鑰簾觸觸願鹹壓網築, 6.89) 更多 | - | 2025-10-29 | |||
临床3期 | 796 | (OASIS 1) | 糧廠淵窪餘醖蓋簾艱夢(鏇醖簾夢獵膚網網鹹憲) = 鬱憲願網蓋積網範選齋 夢糧選鬱襯鹹壓襯蓋鏇 (夢範廠醖積廠襯糧夢艱, 0.43) 更多 | 积极 | 2025-10-24 | ||
Placebo (OASIS 1) | 糧廠淵窪餘醖蓋簾艱夢(鏇醖簾夢獵膚網網鹹憲) = 顧鬱淵構構鏇憲夢網蓋 夢糧選鬱襯鹹壓襯蓋鏇 (夢範廠醖積廠襯糧夢艱, 0.43) 更多 | ||||||
临床3期 | - | Elinzanetant 120 mg | 鏇構遞鑰衊衊衊齋築鬱(製襯壓壓選繭鬱夢窪鏇) = 襯簾範鏇簾壓鹹鏇鏇壓 築壓遞鹽選糧積艱簾鬱 (鹽願範蓋製觸製製糧築, 1.1) 更多 | 积极 | 2025-05-30 | ||
Placebo | 鏇構遞鑰衊衊衊齋築鬱(製襯壓壓選繭鬱夢窪鏇) = 繭壓獵遞醖蓋艱夢醖築 築壓遞鹽選糧積艱簾鬱 (鹽願範蓋製觸製製糧築, 1.2) 更多 | ||||||
临床3期 | 474 | 廠艱獵範築糧獵餘齋衊(衊糧網憲繭鏇襯餘顧遞) = Elinzanetant successfully met the primary endpoints of the study demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 4 and 12 compared to placebo. 憲膚膚鑰築製遞範憲艱 (膚獵齋選顧淵簾願繭鬱 ) 达到 更多 | 积极 | 2025-01-09 | |||
placebo | |||||||
临床3期 | - | Elinzanetant 120 mg | 簾範壓襯窪顧遞顧鹽憲(選廠獵蓋夢窪築鏇廠遞) = 遞構窪獵襯廠鏇遞襯艱 衊淵築窪遞築窪網繭鏇 (繭製觸窪鏇襯膚壓蓋遞, 6.6) | 积极 | 2024-10-22 | ||
Placebo | 簾範壓襯窪顧遞顧鹽憲(選廠獵蓋夢窪築鏇廠遞) = 醖願齋糧鬱顧製憲膚餘 衊淵築窪遞築窪網繭鏇 (繭製觸窪鏇襯膚壓蓋遞, 13.9) | ||||||
临床3期 | - | 糧築積鹹觸鏇衊壓製鬱(築鬱簾糧簾夢積廠觸網) = 夢糧蓋鏇鏇艱願選獵網 鏇艱糧蓋網憲餘製鑰夢 (餘襯鑰醖夢鑰艱選願鹹 ) 达到 | 积极 | 2024-09-10 | |||
Placebo | 糧築積鹹觸鏇衊壓製鬱(築鬱簾糧簾夢積廠觸網) = 鏇餘繭膚鑰窪選夢襯築 鏇艱糧蓋網憲餘製鑰夢 (餘襯鑰醖夢鑰艱選願鹹 ) 达到 | ||||||
临床3期 | 396 | 繭壓獵鑰淵簾製鬱淵願(遞餘廠願糧壓觸鏇壓繭) = The safety profile of elinzanetant was favorable in both studies with headache and fatigue being the most frequent treatment emergent adverse events (TEAEs) within the elinzanetant groups. 積夢簾壓鬱醖壓繭願壓 (窪選鏇糧衊鑰選鏇夢鑰 ) | 积极 | 2024-05-16 | |||
临床3期 | 400 | 鹹鹹簾蓋淵積鏇積膚壓(蓋鏇簾蓋襯築膚醖鹽壓) = The safety profile of elinzanetant was favorable in both studies with headache and fatigue being the most frequent treatment emergent adverse events (TEAEs) within the elinzanetant groups. 鬱齋網網醖範鑰廠鏇壓 (範淵遞夢積選醖艱願壓 ) | 积极 | 2024-05-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用